



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Review

# Molecular methods for pathogen and microbial community detection and characterization: Current and potential application in diagnostic microbiology

Christopher D. Sibley<sup>a</sup>, Gisele Peirano<sup>d</sup>, Deirdre L. Church<sup>b,c,d,\*</sup>

<sup>a</sup> Department of Microbiology, Immunology & Infectious Diseases, Faculty of Medicine, University of Calgary, Calgary, Alta, Canada

<sup>b</sup> Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of Calgary, Calgary, Alta, Canada

<sup>c</sup> Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, Alta, Canada

<sup>d</sup> Division of Microbiology, Calgary Laboratory Services, Calgary, Alta, Canada

## ARTICLE INFO

## Article history:

Received 10 September 2011

Received in revised form 10 January 2012

Accepted 12 January 2012

Available online 9 February 2012

## Keywords:

Molecular methods

Pathogen

Diagnostic

Identification

Microbial community

## ABSTRACT

Clinical microbiology laboratories worldwide have historically relied on phenotypic methods (i.e., culture and biochemical tests) for detection, identification and characterization of virulence traits (e.g., antibiotic resistance genes, toxins) of human pathogens. However, limitations to implementation of molecular methods for human infectious diseases testing are being rapidly overcome allowing for the clinical evaluation and implementation of diverse technologies with expanding diagnostic capabilities. The advantages and limitation of molecular techniques including real-time polymerase chain reaction, partial or whole genome sequencing, molecular typing, microarrays, broad-range PCR and multiplexing will be discussed. Finally, terminal restriction fragment length polymorphism (T-RFLP) and deep sequencing are introduced as technologies at the clinical interface with the potential to dramatically enhance our ability to diagnose infectious diseases and better define the epidemiology and microbial ecology of a wide range of complex infections.

© 2012 Elsevier B.V. All rights reserved.

## Contents

1. Introduction	505
2. Pathogen detection, surveillance and discrimination	506
2.1. Real-time PCR	506
2.2. DNA target sequencing	507
2.3. Molecular typing	508
3. Pathogen discovery and characterization	508
3.1. Broad-range PCR	508
3.2. Broad-range PCR with electrospray ionization mass spectrometry detection	510
3.3. Microarrays	511
4. Microbial community analysis	512
4.1. Terminal restriction fragment length polymorphism (T-RFLP)	513
4.2. Deep sequencing	513
4.3. Other clinical applications of deep sequencing	515
5. Future directions	515
References	516
Further reading	521

## 1. Introduction

Defining the etiological agent(s) of infection facilitates more effective patient management by tailoring specific targeted antibiotic therapy. Clinical microbiology laboratories worldwide have historically relied on phenotypic methods (i.e., culture and biochemical

\* Corresponding author. Address: c/o Calgary Laboratory Services, 9-3535 Research Rd. N.W., Calgary, Alta, Canada T2L 2K8. Tel.: +1403 770 3281; fax: +1403 770 3347.

E-mail address: [Deirdre.church@cls.ab.ca](mailto:Deirdre.church@cls.ab.ca) (D.L. Church).

tests) for detection, identification and characterization of virulence traits (e.g., antibiotic resistance genes, toxins) of human pathogens. However, limitations to implementation of molecular methods for human infectious diseases testing are being rapidly overcome allowing for the clinical evaluation and implementation of diverse technologies with expanding diagnostic capabilities. Molecular methods have been increasingly exploited to diagnose classic and fastidious pathogens, since the advent of the polymerase chain reaction (PCR) (Mullis and Faloona, 1987). Some infectious agents identified and largely characterized in the past two decades using molecular methods include; Hepatitis C virus (Choo et al., 1989), *Tropheryma whippelii* (Relman et al., 1992), *Mycobacterium genavense* (Bottger et al., 1992), *Bartonella* (previously *Rochalimaea*) *henselae* (Matar et al., 1993), Hantavirus (Sin Nombre virus) (Chapman and Khabbaz, 1994), *Chlamydia pneumoniae* TWAR agent (Kuo et al., 1995), Herpesvirus 8 (Huang et al., 1995), the SARS Coronavirus (Drosten et al., 2003; Ksiazek et al., 2003), Metapneumovirus (Mackay et al., 2003), and Influenza A H1N1 (Renesto et al., 2000; Dawood et al., 2009).

Commercial suppliers have been steadily expanding the number of molecular diagnostic assays for infectious diseases testing (<http://www.fda.org>). Despite these continuing advances, a microbial etiology remains to be defined in a number of cases of human disease that have epidemiological, clinical and/or histological features of infection. Worldwide populations are increasingly being put at risk for novel contagions, particularly zoonotic agents or bacterial pathogens carrying acquired antimicrobial resistance genes (Church, 2004). Broad application of highly sensitive molecular technologies to common infections is also revealing that these diseases are not mono-microbial as previously thought, but rather, due to a disorder in complex microbial communities.

The human microbiome comprises 100 trillion microbial cells, outnumbering the somatic cells in the body by at least an order of magnitude (Savage, 1977). It was suggested early on that in order to properly appreciate human biology the 30,000 genes encoded in the human genome must be placed in the context of the millions of genes encoded by our microbial counterparts that inhabit the gastrointestinal tract, the genitourinary tract, the oral cavity, the nasopharynx, the respiratory tract, and the skin (Davies, 2001). The human microbiome project was designed to sequence 1000 novel bacterial reference genomes and the entire collective of microbial genomes from 250 healthy individuals (Turnbaugh et al., 2007; Peterson et al., 2009). A vast number of human commensal microbial species have yet to be identified and characterized. The composition of the human microbiota is unique and varies significantly between body sites. A recent study showed that 3.3 million non-redundant genes (150 fold greater than the human genome) were assembled from 1000 to 1150 distinct microbial species from 124 human gut samples (Qin et al., 2010). The diversity of the human microbiome is also affected by environmental factors, diet, and the host immune system (Ley et al., 2006). The essential role that commensal micro-organisms play in human health is becoming increasingly recognized for its functional involvement in normal development, nutrition, immune regulation and colonization resistance (Brook, 1999; Hooper, 2004; Mazmanian et al., 2005; Li et al., 2008; Clarke et al., 2010). There is also evidence accruing that the functional capacity of the human microbiome may be altered in patients with obesity and other chronic conditions (Qin et al., 2010).

The molecular methods for diagnostic microbiology are diverse. The advantages and limitation of techniques including real-time polymerase chain reaction, partial or whole genome sequencing, molecular typing, microarrays, broad range PCR and multiplexing will be discussed. Finally, terminal restriction fragment length polymorphism (T-RFLP) and deep sequencing are introduced as technologies at the clinical interface with the potential to dramat-




Fig. 1. Principles of real-time PCR Probes\*\*. \*\*Illustration from Heid et al. (1996).

ically enhance our ability to diagnose infectious diseases and better define the epidemiology and microbial ecology of a wide range of complex infections.

## 2. Pathogen detection, surveillance and discrimination

Diagnosis of infectious diseases by using PCR involves target amplification methods and often nucleic acid sequence analysis of the amplicon. Unlike phenotypic characteristics that may be variable, molecular amplification methods take advantage of the use of stable genotypic characteristics. Another major diagnostic advantage of PCR is that the detection of nucleic acid does not require the labor intensive cultivation of microbial biomass. The bacterial genome provides variable regions for species identification and virulence factors or toxins loci can be useful for defining the pathogenicity of an organism. In addition to standard PCR, complete genome sequences have greatly facilitated the rapid development of other molecular identification methods for pathogen detection including nucleic acid hybridization (probes) (Procop, 2007), ligase chain reaction (Drancourt et al., 2000), strand-displacement amplification (SDA) (Walker et al., 1992a,b), transcription-based amplification (TAS, TMA, NASBA and 3SR) (Kwoh et al., 1989; Compton, 1991; Fahy et al., 1991) and loop-mediated isothermal amplification (LAMP) (Notomi et al., 2000). The enormous amount of nucleic acid sequence data from human pathogens has enhanced the diagnostic capabilities of sequenced-based identification and genotyping methods of both common and uncommon micro-organisms (Fournier and Raoult, 2011).

### 2.1. Real-time PCR

Despite the development of alternative amplification technologies, PCR remains the most widely used method in both research and diagnostic laboratories for pathogen detection (Lisby, 1998;

Mothershed and Whitney, 2006; Procop, 2007). Conventional PCR assays designed for single target detection have been broadly utilized by most large diagnostic microbiology laboratories for the past 15 years (Lisby, 1998). Targets for human pathogens are based on specific loci for taxonomic identification, important phenotypic traits (such as antimicrobial resistance determinants), or virulence factors (Mothershed and Whitney, 2006).

Real-time PCR detection using probes is illustrated in Fig. 1 (Heid et al., 1996). The targets are detected in real time from the sealed PCR plate and there is no post-PCR processing required (Whitcombe et al., 1998), therefore, the risk of false-positive results due to amplicon carryover is substantially decreased compared to conventional PCR (Barken et al., 2007). In addition, most real-time PCR formats offer the option of melting curve analysis so that the amplicon can be distinguished from nonspecific product or primer-dimers (MacKay 2007; Tevfik Dorak, 2006). The performance of real-time PCR assays therefore has increased sensitivity and reliability of the reported results compared to those obtained by conventional PCR (Espy et al., 2006; Mothershed and Whitney, 2006; Procop, 2007). Real-time PCR assays can be designed to allow the detection and simultaneous quantification of the PCR products over a wide dynamic range of quantitative linearity, which is an important requirement of many diagnostic applications (Croagh et al., 2010; Itakura et al., 2011; Luft et al., 2011). Because real-time PCR assays are amenable to automation, most of these detection assays are run and completed in the clinical laboratory setting in a shorter time than conventional PCR, therefore providing a more rapid test cycle turnaround time. Real-time PCR has truly become ‘walk-away’ molecular testing in the clinical laboratory setting. Despite this benefit, cost is a limitation of implementation in smaller laboratories with limited resources because of instrument cost and the price of a single real-time PCR reaction including DNA extraction can be more than three times of the cost of conventional PCR (Mothershed and Whitney, 2006).

While commercially available PCR assays (kits) initially focussed on the detection of sexually transmitted infections and blood-borne viruses, the conversion to fluorescence based methods is resulting in rapidly expanding menus of human diagnostic real-time PCR assays developed in-house as well as commercially (<http://www.fda.org>) (Renesto et al., 2000; Edberg et al., 2008; Heymans et al., 2010; Scott et al., 2010; Diene et al., 2011; Hadfield et al., 2011; Kruttgen et al., 2011; Lehours et al., 2011; Luo et al., 2011; Luong et al., 2011; Nakauchi et al., 2011; Polley et al., 2011; Thurman et al., 2011; Touinssi et al., 2011; Wilson et al., 2011; Wolffs et al., 2011; Xu et al., 2011). Many more real-time PCR assays for detecting pathogens are currently in development and include detection of vancomycin-resistant enterococci and *Clostridium difficile*. In the near future, clinical laboratories will be able to perform many different types of monoplex and multiplex real-time PCR assays for screening, detection or nosocomial surveillance on the same automated instrument system akin to the performance of high-volume infectious diseases serological testing on automated instruments that perform enzyme immunoassay testing.

## 2.2. DNA target sequencing

Nucleic acid sequencing has emerged as important tool for pathogen identification and discovery. Identification of human pathogens by partial or whole gene sequencing had not been widely adopted by clinical microbiology laboratories even a decade ago due to the labor and expense of bringing this technology in-house, the lack of standardized methods for conducting analyses, and interpreting the results. Prior to 2000, DNA target sequencing had been primarily used for identification of organisms that were difficult to identify by using conventional phenotypic methods or

recover by cultivation (Woo et al., 2008; Pareek et al., 2011). DNA target sequencing for the rapid identification of bacterial, viral and fungal pathogens has since been increasingly implemented as a routine procedure by many clinical laboratories. In the last decade, DNA sequencing technologies have improved throughput capability and cost. Important guidelines have been published that provides interpretive criteria for identification of a wide range of clinically important bacteria and fungi to the species and genus levels (Petti et al., 2008a). Commercial software is available that provides a quality assured database of known bacterial and fungal sequences for human pathogens (SmartGene® IDNS, Lausanne, Switzerland) (Simmon et al., 2006). Some diagnostic laboratories also perform sequencing analysis of viral cDNA generated by reverse transcription (Fournier and Raoult, 2011).

Sanger-based sequencing technology remains the most commonly used method, although newer non-electrophoresis methods (i.e., pyrosequencing, ion-torrent sequencing) are increasingly being used for clinical applications because of their improved efficiency and decreased cost (discussed later). DNA target sequencing for routine identification utilizes conserved genes for both bacteria and fungi that have been widely used for taxonomic purposes (Bottger, 1989; Doolittle, 1999; Atkins and Clark, 2004; Petti, 2007). In bacteria, the rRNA genes (5S, 16S, and 23S) and their intergenic regions have been commonly used for taxonomic purposes. These genes are universally present, are only minimally affected by horizontal gene transfer and contain hypervariable regions flanked by high sequence conservation. These characteristics have made the 16S rRNA gene the most widely used region for bacterial taxonomy and identification (Doolittle, 1999). The sequence information obtained from the 5' portion of the 16S rRNA gene often provides sufficient data for identification purposes (Petti, 2007; Woo et al., 2008). Much of the data in public databases also correspond to this region of the 16S rRNA gene (e.g., GenBank). Occasionally, the entire 1540 bp region is required to distinguish between particular taxa or strains, or alternative DNA gene targets may also have to be interrogated because some species may share 99–100% 16S rRNA sequence identities (Facklam, 2002; Janda and Abbott, 2002). Alternative gene targets for speciation have been used including *recA*, *rpoB*, *tuf*, *gyrA*, *gyrB* and *cpn60* family proteins because of functionally conserved regions with intervening variability. In fungi, the eukaryotic rRNA gene complex consists of four ribosomal genes, 18S (small subunit), 5.8S, 28S (large subunit), and 5S genes. Within this region, the internal transcribed spacer (ITS) (White et al., 1990) and an approximately 600 bp D1/D2 region of the 28S subunit (Kurtzman and Robnett, 1997) are the most phylogenetically variable regions and have been widely used for fungal taxonomy and identification (Atkins and Clark, 2004; Petti et al., 2008a).

Several investigators have compared the performance of 16S rRNA gene or fungal ITS gene sequencing with conventional phenotypic methods and commercial automated systems for the identification of human pathogens. Overall, DNA target sequencing provides a somewhat higher rate of species identifications than phenotypic methods with an accuracy between 62% up to 92% depending on the group of bacteria studied and the criteria used to define a species (Bosshard et al., 2003a, 2004, 2006; Heikens et al., 2005; Simmon et al., 2006, 2008b). The 16S rRNA gene target will not however discriminate many species within the Enterobacteriaceae or closely related Staphylococcus, Enterococcus or Streptococcus species (Petti, 2007; Petti et al., 2008a,c). Similarly, fungal sequencing using the ITS or D1/D2 gene regions provides excellent identification compared to phenotypic methods and allows much more rapid identification of non-sporulation molds and rare yeasts that are difficult to identify using classical methods (Ciardo et al., 2007, 2010; Borman et al., 2008, 2010; Pounder et al., 2007).

### 2.3. Molecular typing

Molecular typing of bacterial isolates is required for infectious diseases epidemiological surveillance, to detect laboratory cross contamination, distinguish relapse from re-infection, and for surveillance during infectious outbreaks (van Belkum et al., 2007). Molecular typing is therefore crucial for source tracking and epidemiology (van Belkum et al., 2007; Fournier and Raoult, 2011). Van Belkum and colleagues published a comprehensive review and guidelines for the validation and application of molecular typing methods for use in bacterial epidemiology (van Belkum et al., 2007). Among non-sequence-based methods, pulsed-field gel electrophoresis (PFGE), which separates macro-restriction DNA fragments has been the “gold standard” technique used by clinical laboratories to examine the molecular relatedness of bacterial isolates as well as yeasts and fungi (Beadle et al., 2003). Provided that the PFGE method and interpretation are carefully standardized for a given microorganism, this method has robust reliability and intra- and inter-laboratory reproducibility (Goering, 2010). Similar DNA fragment-based methods have also been developed and used for clinical analyses including; restriction endonuclease fingerprinting analysis (REA) (Falk et al., 1985), plasmid typing (Farrar, 1983; Mayer, 1988; Nicolle et al., 1992), ribotyping (Thomson-Carter et al., 1989), PCR fingerprinting (Welsh and McClelland, 1990), restriction fragment length polymorphism (RFLP) (Goh et al., 1992; Metzgar et al., 1998), and amplified fragment length polymorphism (AFLP) (Vos et al., 1995; Meudt and Clarke, 2007). Multi-locus variable number tandem repeat analysis (MLVA) is another PCR-based method, which is used to determine the number and length of variable number tandem repeats (VNTRs) present in a genome due to slipped mispairing (van Belkum et al., 1998; Fournier et al., 2007). Several MLVA systems have been developed for interpretation of a variety of species (van Belkum et al., 2007) but few multicentre studies have been done (Francois et al., 2005; Kremer et al., 2005).

Due to the dedicated expertise, labor and specialized equipment needed to perform PFGE and other fragment-based methods, clinical laboratories are increasingly turning to more rapid, semi-automated, PCR-based or sequence-based methods to perform either rapid initial or routine genotyping analyses. The Diversilab system performs semi-automated repetitive-PCR analysis (Healy et al., 2005) and has good to excellent agreement compared to several other typing methods for distinguishing several different types of micro-organisms (Fluit et al., 2010; Overdevest et al., 2011; Deplano et al., 2011) including methicillin-resistant *Staphylococcus aureus* (MRSA) (Tenover et al., 2009; Babouee et al., 2011; Church et al., 2011a), vancomycin-resistant *Enterococcus* (Chuang et al., 2010; Bourdon et al., 2011), and commonly encountered dermatophytes dematophytes, *Candida* and fungi (Pounder et al., 2005,2006; Wise et al., 2007; Hansen et al., 2008). This method has also been used to genotype *Acinetobacter baumannii* outbreaks strains, and extended-spectrum B-lactamase producing *Escherichia coli* and *Klebsiella pneumoniae* isolates (Pitout et al., 2009; Brolund et al., 2010; Higgins et al., 2012). Semi-automated rep-PCR (Diversilab) however does not always provide the same discrimination power as PFGE or other typing methods (Babouee et al., 2011; Bourdon et al., 2011; Brolund et al., 2010; Chuang et al., 2010; Church et al., 2011a,b; Tenover et al., 2009). Recognizing this limitation of this semi-automated platform, Diversilab may nevertheless be a useful tool for the rapid identification of nosocomial outbreaks (depending on the type of bacteria involved) when used in parallel with confirmatory analysis with greater discriminatory power.

Several sequence-based genotyping methods have been used for infection surveillance and the tracking of strain evolution within a given geographic location. Single-locus sequence typing (SLST) uses

the DNA sequence obtained from a highly variable single genetic locus to provide strain discrimination. Genotyping of *Streptococcus pyogenes* using the *emm* locus relies on sequencing of 150 bps coding for the N-terminal of the M protein (Simmon et al., 2008a). Interestingly, SLST typing of *S. pyogenes* has identified more than twice as many M-types as previously shown by using antisera (<http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm>). Many clinical laboratories also now rely on SLST typing of *S. aureus* according to the *spa* gene that encodes protein A. Rapid sequence determination of the *spa*-type may now be automated because of the development of dedicated software for sequence interpretation (Harmsen et al., 2003a,b). The clinical appeal of SLST systems such as the one developed for *S. aureus* are the ability to use existing equipment (many laboratories have automated sequencers) and the excellent site to site reproducibility.

Other sequence-based genotyping methods that incorporate genome sequence data or were designed based on genome sequences, include single-nucleotide polymorphisms (SNPs) typing and multilocus sequence typing (MLST) (Maiden et al., 1998; Chaloner et al., 2011; Hayford et al., 2011; Lilliebridge et al., 2011; van Gent et al., 2011). However, these more expensive, laborious and complex methods have mainly been used for specific population-based microorganism diversity or population-based epidemiological studies, and currently are not widely performed as a diagnostic technique. The identification of single nucleotide polymorphisms (SNP), which is based on identifying point mutations at various genomic loci, has been used for genotypic characterization of several bacterial pathogens (<http://www.ncbi.nlm.nih.gov/projects/SNP>). MLST is based on determining the DNA sequence variation of several housekeeping genes (5–10) and has proven its taxonomic utility largely due to standardized interpretation, publically available software (i.e., eBURST) and the accessibility of databases (<http://www.mlst.net>). Multi spacer typing (MST) relies on a combination of the most variable intergenic spacers between strains (Fournier et al., 2007). Reports using this method are restricted to *Rickettsia* isolates (Fournier and Raoult, 2007).

## 3. Pathogen discovery and characterization

Clinical microbiology laboratories use molecular methods to enhance the detection of pathogen(s) in critical clinical situations whereby phenotypic methods have failed to identify an etiological agent usually because the pathogen is fastidious or uncultivable and/or the patient has been given empiric antibiotic coverage prior to the collection and submission of clinical specimens. The organism may be cultivatable in the later situation but present in such low numbers that phenotypic methods are not sensitive enough for detection. Currently, the two most commonly used methods to detect such organisms include a microarray-based assay and a universal broad-range 16S PCR which utilizes species-specific hybridization probes, sequencing or electro-mass spectrometry for subsequent analysis of the product(s). Next-generation sequencing technologies may also be routinely employed in the future for pathogen detection and discovery in the clinical laboratory.

### 3.1. Broad-range PCR

Although universal broad-range 16S rRNA gene PCR was originally developed for determination of microbial community diversity within complex bacterial populations in extreme environments, it has subsequently been used for pathogen detection where conventional bacteriological techniques fail to produce a diagnostic result (Sontakke et al., 2009). Broad-range PCR offers an important clinical benefit for analysis of critical culture-negative samples as it can detect bacterial nucleic acid present in a sample through targeting

conserved bacterial sequences (described in Section 2.2). Nucleic acid sequencing of amplicon generated by broad-range PCR allows identification of the organism(s) by comparison with known sequences deposited at Genbank or other databases (Drancourt et al., 2000; Janda and Abbott, 2002; Petti, 2007). Previously uncharacterized microbes (novel pathogens) may also be detected because of the universal nature of primers/probes and the high sensitivity for detecting the presence of low copy number targets (Bottger, 1989; Relman and Falkow, 1992; Greisen et al., 1994; Monstein et al., 1996; Drancourt et al., 2000; Mothershed and Whitney, 2006; Procop, 2007).

Several investigators initially used amplification of conserved regions of bacterial ribosomal RNA and amplicon sequencing to identify human pathogens (Bottger, 1989; Wilson et al., 1990). Subsequently broad-range PCR has been extensively used non-selectively to detect bacterial DNA in clinical samples (Monstein et al., 1996; Corless et al., 2000; Nadkarni et al., 2002; Nikkari et al., 2002; Harris and Hartley, 2003; Saravolatz et al., 2003; Xu et al., 2003; Ott et al., 2004; Jordan et al., 2005; Zucol et al., 2006; Fenollar and Raoult, 2007; Rosey et al., 2007; Reier-Nilsen et al., 2009; Chang et al., 2011). Rather than perform multiple multiplex PCR assays on a given sample, broad-range assays are designed such that a single clinical sample can be simultaneously screened for multiple organisms (i.e., any bacterial species); however, amplicons may require cloning prior to sequencing in order to get an accurate result with traditional Sanger-based methods due to the potential mixed nature of amplified products (Grahm et al., 2003). This approach has been successfully applied to clinical samples from normally sterile sites to diagnose invasive bacterial or fungal infections, including culture-negative meningitis, pneumonia and endocarditis. Increasingly, this approach is also being used to identify the putative pathogen(s) in a number of inflammatory diseases, and for detection of known pathogens that are not easily diagnosed using standard methods. *Tropheryma whippelii* was identified as the cause of Whipple's disease using a broad-range molecular PCR (Lepidi et al., 2004). *Helicobacter pylori*, the cause of peptic ulcer disease, has been found to be the dominant microbiota in the human stomach using broad-range molecular analysis (Bik et al., 2006). Broad-range 16S PCR has also been used to detect clinically relevant *Chlamydia* spp. infecting humans and animals (Goldschmidt et al., 2006).

A significant advantage of real-time broad-range PCR assays are the ability to quantify the bacterial load in the sample and the higher analytical sensitivity compared to conventional PCR (Millar et al., 2001; Zucol et al., 2006; Ammann et al., 2007; Fenollar et al., 2008a). The minimal detection limits for conventional broad-range PCR has been determined to be in the range between ten and  $10^3$  CFU or CFU equivalents per PCR (Harris and Hartley, 2003), whereas the reported detection limits for real-time broad-range assays is 10–100X lower with improved sensitivity. Zucol and colleagues developed a broad-range real-time PCR assay method that was able to detect  $\leq 10^2$  CFU in water per reaction but was not tested on clinical samples (Zucol et al., 2006).

Overall sensitivity and detection limits of broad-range PCR assays may also be influenced by several factors including the prior culture enrichment of the sample, the use of good molecular laboratory practices and decontamination procedures, the extraction methods, the choice of universal primers and probes, the assay cycle time and melting temperature, concentration of the amplified products prior to sequencing, and the appropriate use of controls throughout the procedure (Harris and Hartley, 2003; Sontakke et al., 2009). Several studies have shown substantial increases in the sensitivity of broad-range PCR reactions when clinical samples undergo prior culture enrichment in broth or shell vials rather than direct plating prior to molecular analysis (Harris and Hartley, 2003; Gouriet et al., 2005; Saglani et al., 2005). Enrichment culture

of 382 pediatric fluid and tissue samples in a broth medium prior to 16S rDNA PCR identified several pathogens in these samples that were not previously detected by primary plating or direct PCR of extracted DNA from the sample (Harris and Hartley, 2003). Saglani and colleagues also performed 16S broad-range PCR on pleural fluid samples from 32 children with empyema and detected bacterial DNA in 75% of the samples following enrichment culture versus only 18.7% after direct plating (Saglani et al., 2005). Culture-enrichment in parallel with broad-range PCR has also been shown to be an effective means of bacterial recovery and identification from cystic fibrosis sputum (Sibley et al., 2011). Shell vial culture has also been used as an enrichment technique for the growth of fastidious or previously uncharacterized micro-organisms from clinical samples (Gouriet et al., 2005). Human embryonic lung fibroblast and human endothelial cell lines have been used most often followed by 16S broad-range PCR and sequencing to identify the organism.

Initial clinical evaluations of broad-range PCR used conventional methods. However, DNA contamination from other sources including environmental or commensal organisms, PCR reagents including *Taq* polymerase, or even the disposables have been identified as a major concern for broad-range PCR due to the sensitivity of the assay (Corless et al., 2000; Vandecasteele et al., 2002; Mohammadi et al., 2005; Chang et al., 2011). Universal primers and probes that target the 16S rRNA gene have therefore been recently adapted to a real-time broad-range PCR in order to minimize this problem (Kobayashi et al., 2005; Goldschmidt et al., 2006; Zucol et al., 2006; Deutch et al., 2007; Schabereiter-Gurtner et al., 2008).

The universal 16S rRNA gene target and the high sensitivity of PCR can be a limitation due to false positive test results when analyzing clinical samples. Even small amounts of bacterial DNA contamination either within the clinical sample, or introduced during some part of the molecular procedure may result in a false positive broad-range PCR result, or a result that is difficult to interpret because of the amplification of one or more common commensal organism(s). Investigators have outlined several sources of bacterial DNA contamination that may occur during the sample collection, nucleic acid extraction or PCR analysis steps (Millar et al., 2002, 2007; Vandecasteele et al., 2002; Fenollar et al., 2006, 2008b). Despite clinical laboratories having standard operating procedures for the collection of all types of clinical samples, contamination by commensal organisms remains problematic with many specimen types (Blake and Doherty, 2006; Dhillon et al., 2009; Marlowe et al., 2010; Patton and Schmitt, 2010; Ishikawa et al., 2011). DNase or restriction enzymes may also be used to de-contaminate the PCR reaction mixture (Millar et al., 2002; Vandecasteele et al., 2002). Broad-range PCR assays should only be performed using good molecular laboratory practices as previously outlined (Mitchell et al., 2011). In addition, it is critical that a human DNA amplification control as well as a positive and negative control (Tanner et al., 1998; Millar et al., 2002; Bosshard et al., 2003b; Greub et al., 2005; Fenollar et al., 2008b) be included during sample extraction and carried throughout the procedure. Negative controls should consist of a negative sample control (i.e., an aliquot of a known negative clinical sample such as blood from a person without bacteraemia), and a negative reaction mixture control (i.e., contains all reagents but no clinical sample extract) in order to detect reagent contamination. Commercial reagents may also be the source of bacterial contamination and may need to be sterilized using filtration of other methods prior to use (Muhl et al., 2010; Chang et al., 2011).

Currently there is no universal DNA extraction protocol that is effective for both Gram-negative and Gram-positive bacteria and the extraction method impacts the analytical sensitivity of the assay. Prior studies of broad-spectrum PCR have used enzyme treatment (lysozyme, proteinase K), freezing and thawing or boiling,

mechanical disruption, a commercial method (i.e., QiAmp Blood Kit, Qiagen or automated instrument) or a combination of these methods for DNA extraction (Schuurman et al., 2004; Zucol et al., 2006; Rosey et al., 2007; Fenollar et al., 2008b). Zucol and colleagues determined the analytical sensitivities of broad-range RT-PCR based assays employing one to three different genomic DNA extraction protocols in combination with one or three different primer pairs targeting the 16S rRNA gene to detect a panel of 22 bacterial species (Zucol et al., 2006). A DNA extraction protocol using lysozyme, lysostaphin and proteinase K followed by PCR amplification using primers Bak11W/Bak2 (796 bp product), resulted in the best overall sensitivity; 82% of the strains were detected at a low concentration (Zucol et al., 2006). The selection of primers and probes for broad-range PCR assays also effects analytical sensitivity. Primers targeting the 16S rRNA gene are used in most of these assays, while some have also targeted the 23S rRNA gene (Greisen et al., 1994). As outlined by Baker et al. (2003), it is not possible to develop a 16S rRNA gene primer set that will be entirely universal. Therefore, different conserved regions within the 16S rRNA gene and various primer sequences for been employed for analysis of human clinical specimens (Greisen et al., 1994; Baker et al., 2003). The target loci and the primer sequences impact taxonomic assignments. In addition, analysis of existing primer sets demonstrates that environmental organisms within the Archaea and Eukarya can also be detected. Another limitation of this approach is that a definitive identification is not always possible due to the lack and quality of data in public databases as well as insufficient sequence divergence within the 16S rRNA gene sequence between certain taxonomic groupings (Petti, 2007; Petti et al., 2008a; Simmon et al., 2006).

Despite these limitations, the diagnostic utility of broad range 16S rDNA PCR has been evaluated in a variety of clinical conditions including endocarditis, meningitis, bone and joint infections and endophthalmitis (Fenollar and Raoult, 2004; Sontakke et al., 2009). This method has also been used to determine the cause of infection in pediatric patients with fever and neutropenia (Jordan et al., 2005; Ammann et al., 2007; Reier-Nilsen et al., 2009) or culture-negative intracerebral abscesses (Petti et al., 2008b) as well as to determine a cause of death in patients with unexplained mortality and critical illness (Nikkari et al., 2002). The implementation of 16S broad-range PCR to detect and differentiate bacteria in heart valve specimens substantially improves the diagnosis of culture-negative endocarditis (Millar et al., 2001; Marin et al., 2007). Although heart valve culture remains part of the Duke classification scheme for the diagnosis of infectious endocarditis, its poor sensitivity (7.8–25.4%) and specificity (71.6–88.6%) has led several investigators to recommend that culture testing be replaced by broad-range PCR as a major diagnostic criterion because of its much higher sensitivity (range = 41.2–96%) and specificity (95–100%). Several studies have documented the reliability of broad-range PCR for the detection of bacteria in excised heart valves and this assay is being increasingly used in conjunction with blood cultures to determine the microbial aetiology in both blood culture-positive and -negative endocarditis cases (Millar et al., 2001; Moore et al., 2001; Bosshard et al., 2003b; Lepidi et al., 2003, 2004; Breikopf et al., 2005; Greub et al., 2005; Houpiikian and Raoult, 2005; Raoult et al., 2005; Rice and Madico, 2005; Rovey et al., 2005; Marin et al., 2007; Dreier et al., 2008; Munoz et al., 2008; Voldstedlund et al., 2008; Tang, 2009; Fournier et al., 2010; Caram et al., 2008). Broad-range 16S rDNA gene PCR on heart valve tissue allows diagnosis of unusual causative agents of culture-negative endocarditis including *Cardiobacterium hominis* (Mueller et al., 1999), *Bartonella quintana* (Houpiikian and Raoult, 2005; Dreier et al., 2008), *Tropheryma whippelii* (Lepidi et al., 2004; Thuny et al., 2010), *Mycoplasma* spp. (Fenollar et al., 2004) and *Coxiella burnetii* (Issartel et al., 2002; Thuny et al., 2010).

Interpretation of all broad-range PCR results should be correlated with the clinical picture due to the potential for DNA contamination from other sources. A 'positive' broad-range 16S PCR result should be correlated with the patient's clinical history and examination findings along with the results of other pertinent diagnostic test information to determine the likelihood of a particular disease. For example, in the case of a cerebrospinal fluid (CSF) sample testing positive by 16S broad-range PCR for a bacterial meningitis pathogen, the patient's clinical presentation and other CSF test results (i.e., CSF glucose, protein, cell count and culture) should be consistent with a diagnosis of acute meningitis. Further strength is also added to a 16S broad-range result of detection of a rare or unusual pathogen when the same micro-organism is detected in longitudinal samples, multiple samples of the same kind from several patients or several different specimen types. Interpretation of the presence of common specimen/culture contaminants by broad-range 16S PCR may be particularly difficult when the isolate may also be a potential cause of infection (i.e., *Streptococcus viridans* sp. or coagulase negative staphylococci).

The clinical relevance of bacterial DNA detection may also not indicate active infection in patients who have received prior antibiotic treatment since the broad-range PCR assay will also detect nucleic acid from nonviable cells. Broad-range PCR studies for the detection of bacterial DNA in heart valve tissue have clearly demonstrated that bacteria are slowly cleared from tissue despite antibiotic therapy, so that molecular assay results should be interpreted with caution because the bacteria may no longer be viable. Rovey and colleagues showed that bacterial DNA was found on heart valves more often in patients who underwent heart valve replacement while still on antibiotic therapy (60%) versus those having surgery after completion of their antibiotic treatment (37%,  $p = 0.02$ ) (Rovey et al., 2005). The presence of bacterial DNA was however highly correlated with the presence of histological lesions ( $p = 0.0001$ ) and with the presence of bacteria in the tissue Gram stain ( $p < 0.0001$ ).

### 3.2. Broad-range PCR with electrospray ionization mass spectrometry detection

A new commercial high-throughput bioidentification system (PLEX-ID, Abbott Molecular) has recently become available, that combines broad-range PCR using several gene targets (Table 1) with product detection and analysis by electrospray ionization mass spectrometry (PCR/ESI-MS) (Hofstadler et al., 2005; Baldwin et al., 2009). It shows great promise for identifying a broad range of pathogens without prior knowledge of the pathogen's nucleic acid sequence (<http://us.plex-id.com/stystemoverview>) (Ecker et al., 2008; Baldwin et al., 2009). PCR/ESI-MS can also provide results that include information about an organism's genotype, resistance, or virulence profile. Although currently restricted to epidemiological genomic studies and pathogen discovery, this technology may have a major diagnostic advantage in being able to provide detection, identification and characterization of a broad range of pathogens directly from clinical specimens. This instrument also has the potential to process up to 300 samples in a 24 h period.

PCR/ESI-MS has so far had limited clinical evaluation but several recently published studies demonstrate the potential range of human diagnostic applications in rapid detection of bacteraemia, and the identification and typing of a wide range of pathogens (i.e., *S. aureus*, *Candida* spp., *Mycobacterium* spp., *Ehrlichia* spp., Influenza A and other respiratory viruses, and pan-orthopoxviruses) (Eshoo et al., 2009, 2010; Hall et al., 2009; Wolk et al., 2009; Deyde et al., 2010; Metzgar et al., 2010; Chen et al., 2011a,b; Gu et al., 2011; Kaleta et al., 2011; Massire et al., 2011; Wang et al., 2011). However, further validation of PCR/ESI-MS in the clinical laboratory will need to be performed against standard procedures in

**Table 1**  
Broad-range primers for bacteria used for PCR/ESI-MS.

Gene target	Bacterial detection	Primer pairs**
16S rDNA	Universal	346,347,348,361
23S rDNA	Universal	349,360
<i>rpoC</i>	Bacteroidetes, fusobacteria, spirochaetes, bacilli, proteobacteria ( $\alpha/\beta/\gamma$ )	354
<i>rpoC</i>	Proteobacteria ( $\alpha/\beta$ )	363
<i>valS</i>	Some $\gamma$ -proteobacteria: <i>Erwinia</i>	358
<i>rpoB</i>	<i>Pantoea</i> , <i>Pectobacterium</i>	359
<i>rpoB</i>	Proteobacteria ( $\alpha/\beta$ )	362
<i>tufB</i>	Some $\beta$ -proteobacteria: <i>Eikenella</i> , <i>Neisseria</i> , <i>Achromobacter</i> , <i>Bordetella</i> , <i>Burkholderia</i> , <i>Ralstonia</i>	367
<i>rplB</i>	Clostridia, fusobacteria, bacilli, and $\epsilon$ -proteobacteria ( <i>Campylobacter</i> , <i>Helicobacter</i> , <i>Wolinella</i> )	356, 449
<i>infB</i>	Bacilli	352
<i>sspE</i>	<i>Bacillus cereus</i>	355

\*\* Adapted from Baldwin et al. (2009). For specific primer sequences see Hofstadler et al. (2005).

order to demonstrate the role of this system in potentially replacing other identification methods that are currently faster or as fast while being much less expensive to perform.

### 3.3. Microarrays

Microarrays are used as a high-throughput large-scale screening systems that allow for simultaneous identification and characterization of a very large number (up to several hundred thousand) of alleles of interest. Microarrays are therefore a very powerful tool with greater capacity (100–1000X) compared to other molecular methods (i.e., real-time PCR) that can only analyze a small number of targets. Microarray-based genotyping can potentially identify new genes by including sequences derived from related bacteria or identify polymorphisms that are detectable by oligonucleotide hybridization (Miller and Tang, 2009). DNA microarrays are also being used to diagnose infection by the identification of pathogens and simultaneous detection of drug-resistance and virulence-associated traits in these isolates (Bager et al., 1999).

Technical details of various microarray configurations including probe length and synthesis, number of possible features (i.e., density of the microarray), and the solid-surface used have been previously outlined in detail (Bager et al., 1999; Miller and Tang, 2009). Briefly, all microarrays consist of millions of pre-designed and developed oligonucleotide probes (i.e., consisting of either dsDNA, PCR amplicons 200–800 bp from a known genetic sequence, shotgun library clones or cDNA) that are specifically bound and immobilized on the solid-surface support of the array. The target nucleic acid extracted from a pathogen or clinical specimen of interest is fluorescently labeled and subsequently hybridized to the probe matrix of the microarray. A successful hybridization event between the labeled target molecule and an immobilized probe oligonucleotide creates increased fluorescence intensity above the background level, which can then be measured using either a fluorescent scanner or a flow cytometer. The large amount of complex data generated from a microarray assay can then be analyzed by using a variety of methods with sophisticated bioinformatics algorithms (Zhang et al., 2009; Kaewwongsri et al., 2010; Loewe and Nelson, 2011).

Manufacturing and genomic advances that have allowed expanded development of several commercial microarray formats include solid-support, high-density bead-bead, electronic and liquid suspension bead-based arrays that can be performed and analyzed using bioinformatics software on an automated system (Miller and Tang, 2009). Traditionally, the probes were printed onto glass slides, but commercial systems rely on several other

techniques for microarray production and spatial matrix arrangement including: (i) *in situ* synthesis of the oligonucleotides onto the surface of a quartz wafer (GeneChips® Affymetrix), (ii) high-density bead arrays (SAM, Sentrix BeadChip, Illumina, San Diego, CA), (iii) low-density electronic arrays that use a microelectronic device (NanoCHIP® 400, Nanogen, San Diego, CA), and (iv) liquid-based suspension bead-based arrays that use colored microspheres for the solid support of applied probes (Luminex Corp., Austin, TX).

Microarrays theoretically appear to be an ideal technology for clinical microbiology application because pathogens could be not only detected and identified, but also genotyped and further profiled to determine antimicrobial resistance and virulence traits using a single test. Although microarrays are used for complex human genetics applications they have not been as widely used by clinical microbiology laboratories but are increasingly being implemented for simultaneous detection, identification and genotyping of important viral infections. The major factors limiting implementation of printed and commercial microarray assay formats in the clinical microbiology setting are outlined in Table 2 (Miller and Tang, 2009). Although several commercial suppliers have developed infectious diseases microarrays for research purposes or will manufacture customer-specified assays, commercial assays that have been used diagnostically detect a large panel of respiratory viruses (Petti and Hillyard, 2007; Nolte et al., 2007; Pabbataju et al., 2008; Merante et al., 2007) including the only FDA-approved xTAG Respiratory Viral Panel FAST assay (i.e., eight different respiratory viruses including strains of Influenza A, B), which has a liquid suspension bead-based format (Luminex) (Krunic et al., 2007; Merante et al., 2007; Pabbaraju et al., 2008) (Luminex Molecular Diagnostics, Toronto, Ont. Although other commercial NanoChip® Nanogen) microarray panel tests were previously developed for infection testing (human papilloma virus, transplantation, bacterial pneumonia, infection control, tuberculosis and a gastrointestinal panel), the company discontinued its microarray business in 2007. However, a multitude of clinical applications have been or are in development for liquid suspension bead-based microarrays (Luminex), and this method will most likely be successfully developed commercially for other select diagnostic multiplex panel tests (e.g., viral encephalitis panel, antibiotic resistance panel etc.)

Low or middle-density microarray assays are also increasingly being used for diagnostic testing or epidemiological investigations. To date, microarray techniques have been most widely applied for the detection, identification and genotyping of human papilloma viruses (HPV) known to causing cervical dysplasia, and cancer of the cervix and other sites (Hwang et al., 2003; Oh et al., 2004; Albrecht et al., 2006; Gheit et al., 2006; Klug et al., 2008; Ermel et al., 2010; Eklund et al., 2010; Schopp et al., 2010; Cho et al., 2011). Currently there are about 100 identified genotypes of HPV, of which about 40 are genital HPV types that have been assigned to either oncogenic or 'high-risk' or non-oncogenic or 'low-risk' categories based on their detection in cervical cancers (Munoz et al., 2003). Worldwide, HPV types 16 and 18 have been shown to cause the majority of cervical cancers, approximately a half of high grade precancerous lesions and a quarter of low grade lesions, whereas low-risk HPV types 6 and 11 cause most genital warts and some low grade cervical lesions (Munoz et al., 2003; Li et al., 2011). Epidemiologic surveillance of high-risk HPV genotypes is therefore important for not only clinical care but also vaccine development. One of the earliest studies of the clinical efficacy of an HPV oligonucleotide microarray for detections of 15 types of high-risk HPVs (16/18/31/33/35/39/45/51/52/54/58/59/66/68/69), and seven types of low-risk HPVs (6/11/34/40/42/43/44) from various histological cervical lesions showed that this was a highly comparable method to PCR-RFLP analysis; HPV DNAs were detected in 158 and 174 of the 234 cervical samples by PCR-RFLP compared to



**Table 2**  
Major advantage and disadvantages of various microarray formats for diagnostic purposes\*\*.

Format	Supplier	Advantages	Disadvantages
Printed arrays	In-house manufacture by a core facility NimbleGen (Roche) Agilent	<ul style="list-style-type: none"> <li>• Inexpensive</li> <li>• Simple to manufacture</li> <li>• Flexibility to change spot probes as required</li> <li>• Assay steps manual</li> </ul>	<ul style="list-style-type: none"> <li>• Need reliable access to a core facility (dust, humidity and temperature controlled)</li> <li>• Little supervision over quality control of manufacture</li> <li>• Requires extensive in-house probe design and manufacture</li> <li>• Requires expensive assay validation</li> <li>• Requires access to in-house bioinformatics to analyze and assess quality of the data</li> <li>• Can be inflexibility to change assay probes as required</li> <li>• Can be non-conductive to user-defined development (exception: Agilent)</li> </ul>
In-situ synthesized oligonucleotide arrays	GeneChip® (Affymetrix)	<ul style="list-style-type: none"> <li>• Custom-assay production</li> <li>• Automated</li> </ul>	<ul style="list-style-type: none"> <li>• Most expensive</li> <li>• High-density so (15,000 to &gt;10<sup>6</sup>) spot probes per assay</li> <li>• Complex to manufacture – probes chemically synthesized directly on quartz wafers</li> </ul>
Electronic	NanoChip® (Nanogen)	<ul style="list-style-type: none"> <li>• Electric fields promote active hybridization to nucleic acids onto a microelectronic device</li> <li>• Low-density (400 maximum) but adequate for diagnostic panel assays</li> <li>• Less expensive than high-density format</li> <li>• Allows flexible testing of multiple targets in a single sample or multiple samples on the same microarray cartridge</li> </ul>	<ul style="list-style-type: none"> <li>• Commercially available products discontinued (2007)</li> </ul>
Liquid-based suspension bead-based arrays	Luminex Molecular Diagnostics	<ul style="list-style-type: none"> <li>• Probes or universal sequence tags are attached to spectrally unique microspheres; bead hybridization with fluorescently labeled target DNA measured by flow cytometry</li> <li>• Low-density (100 maximum) but adequate for diagnostic panel assays</li> <li>• Less expensive than high-density format</li> <li>• Only FDA-approved commercial assay (xTAG Respiratory Panel)</li> <li>• Most flexible, practical format for clinical use</li> <li>• Multitude of clinical applications</li> </ul>	<ul style="list-style-type: none"> <li>• Requires careful validation of the positive fluorescent threshold for each analyte in a user-defined multiplex-bead-based assay</li> </ul>

\*\* Adapted from Miller and Tang (2009).

HPV microarray method, respectively (Hwang et al., 2003). Subsequent studies have compared several commercial HPV detection and genotyping assays, and highlighted the differences in their performance with regards to type-specific detection rates of various HPV genotypes (Klug et al., 2008; Ermel et al., 2010; Eklund et al., 2010; Schopp et al., 2010; Cho et al., 2011). Eklund and colleagues (2010) for the WHO HPV Laboratory Network recently performed a global proficiency study of HPV genotyping used in HPV surveillance and vaccinology by distributing 43 coded samples composed of titration series of purified plasmids of 16 HPV types (6/1/16/18/31/33/35/39/45/51/52/56/58/59/66/68) whereby detection of at least 50 IU of HPV 16 or HPV 18 DNA and of 500 genome equivalents of the other 14 less prevalent HPV types was considered proficient. Participating laboratories used more than 21 HPV-genotyping assays including the Linear Array (Roche), Lineblots (in-house, PGMY), InnoLiPa (Innogenetics), DNA chip (Biocore), as well as type-specific real-time PCR (GenoID), PCR-RFLP, PCR-Luminex (Multimetrix), PCR sequencing and microarray assays (Papillocheck, Genetel, in-house). HPV 16 and 18 were detected in 98.7% and 92.2% of the data sets, respectively, while less common HPV types 56, 59 and 68 were detected in less than 80% of the data sets. Aside from non-detection of specific HPV types, false-positive HPV genotyping results occurred for two commercial tests and were also reported in twenty-eight data sets which also were considered nonproficient. Although the sensitivity of HPV tests for detection in cervical screening programs need not be as high for less commonly encountered oncogenic HPV types, clinical laboratories need to know the limitations of various microarray methods

and follow recently published guidelines for evaluation of such tests before implementation (Meijer et al., 2009).

Several evaluations have also been done of microarrays that simultaneously assess a large number of microbial gene targets in order to detect and identify pathogens from clinical samples. However, sensitivity of microarray assay detection and identification of pathogens from clinical samples is highly dependent on target gene(s), and enhanced by specific microbial gene amplification before analysis by the array. Either a broad-range or a multiplex PCR is commonly used that targets conserved regions within the 16S bacterial and 28S fungal and intergenic transcribed spacers (ITSs) in rRNA genes prior to microarray analysis of downstream PCR products instead of relying on DNA target sequencing (Rood et al., 2008). An early application of this approach was the panel detection of 40 predominant human intestinal bacterial pathogens from clinical stool samples (Blyn et al., 2008; Ecker et al., 2008). Other clinical applications of user-defined microarrays include; rapid detection and characterization of methicillin-resistant *S. aureus* (MRSA) (Koessler et al., 2006), detection of antimicrobial resistance genes (Bager et al., 1999), and microbial typing of bacterial enterocolitis pathogens (Volokhov et al., 2003; Fitzgerald et al., 2007).

#### 4. Microbial community analysis

Characterizing the properties of pathogenic microbial communities is a new frontier for clinical microbiology because studies of the human microbiome demonstrate that there are far more

unique species present at many body sites than are easily grown in the clinical laboratory (Turnbaugh et al., 2007). Several recent molecular studies of clinical samples from cystic fibrosis patients (Sibley et al., 2008a,b) as well as complex abscesses (Versalovic, 2009) have demonstrated the presence of a far more complex microbial flora than was previously found using phenotypic methods. Classic culture-based methods have most likely given clinical microbiologists a skewed view of the complex microbial community involved in some infections because only the cultivatable pathogens present in high numbers in a given clinical sample may be detected and reported (Petrosino et al., 2009). *Escherichia coli* is the prototypical gut micro-organism but this organism belongs to the  $\gamma$ -proteobacteria phylum, which in its entirety only represents <1% of the total microbial population in the human intestine (Hamady and Knight, 2009). *E. coli* has been thought of as a dominant resident in the human gut solely because it is readily cultivated *in vitro*.

Because of the far greater discriminatory sensitivity of culture-independent approaches, molecular methods are fundamental for characterizing complex human-associated microbial communities. Culture-independent molecular technologies have typically relied on either direct nucleic acid sequencing or electrophoresis in order to investigate community structure, community dynamics and community behavior (Rogers and Bruce, 2010). However, the revolution in high-throughput sequencing technologies in the last decade has allowed for unprecedented data output, orders of magnitude beyond traditional Sanger-based sequencing, at a fraction of the cost per nucleotide (Pallen et al., 2010). Several high throughput sequence-independent community-profiling approaches are also available and include denaturing gradient gel electrophoresis (Muyzer et al., 1993), automated ribosomal intergenic spacer analysis (Fisher and Triplett, 1999) and terminal restriction fragment length polymorphism (T-RFLP) analysis (Liu et al., 1997). Here we will describe T-RFLP and deep 16S rRNA gene sequencing as tools for profiling microbial communities.

#### 4.1. Terminal restriction fragment length polymorphism (T-RFLP)

T-RFLP is an approach that has been extensively used to profile fungal, archeal and eubacterial communities and has comprehensively been reviewed in the context of other fingerprinting techniques in the past (Schutte et al., 2008). Traditionally, it has been used to profile environmental communities but it has also been exploited to investigate microbial communities associated with the oropharynx, gastrointestinal tract, lungs, vagina and other body sites (Rogers et al., 2003; Coolen et al., 2005; Sibley et al., 2008b; Yamamoto et al., 2009; Jakobsson et al., 2010). The technique utilizes one or both PCR primers labeled with a fluorescent dye (labeling both forward and reverse primers can improve resolving power) to amplify the universal 16S rRNA gene from a bacterial community of interest. The resulting amplicon is digested with one or multiple restriction enzymes (at four base pair recognition sequences), salts and primers are removed and the relative abundance of terminal restriction fragments (T-RFs) are resolved by polyacrylamide gel or capillary electrophoresis. The resulting data represents a semi-quantitative profile of the most dominant community members.

T-RF size is estimated by reference to internal size standards and the abundance is expressed as either peak height or peak area. T-RFs are assigned to operational taxonomic units or “bins”. Accurate sizing of T-RFs can be challenging due to the fact that electrophoretic mobility can be influenced by sequence composition (Kaplan and Kitts, 2003) and fluorophores each have different electrophoresis properties (Tu et al., 1998). For this reason, comparisons between profiles should be done only between data generated with the same fluorophore. It is also known that

discrepancies between true and experimentally determined T-RFs can exist (Kaplan and Kitts, 2003).

T-RFLP is inexpensive, high throughput, reproducible and can be a very effective tool for characterizing the dynamic changes that occur in human-associated microbial communities over time (Sibley et al., 2008b). Importantly, the technique is best suited for microbial communities with low to intermediate richness; in populations with greater than 50 distinct organisms the resolving power can be significantly reduced (Engebretson and Moyer, 2003). Like all PCR-based assays, the technique suffers from amplification bias. Appropriate primer selection is essential; however, it must be noted that a catchall, perfect universal primer set does not exist for community profiling (Marsh et al., 2000). Programs are available to optimize primer design and selection but can be limited by the incompleteness of current databases (Collins and Rocap, 2007).

The T-RFLP technique can suffer from the fact that a baseline to distinguish between signal and noise is not necessarily automated; both peak height and area can be used in the determination of this threshold. Several different strategies have been employed and include using a fixed detection threshold, a fixed percentage threshold (Sait et al., 2003), variable percentage thresholds (Osborne et al., 2006), use of a correction factor (Dunbar et al., 2001) and statistical methods (Abdo et al., 2006), each with their advantages and disadvantages (Schutte et al., 2008).

Web-based *in silico* prediction tools are available for microbial identification from T-RFLP data (Kent et al., 2003; Shyu et al., 2007) but these tools suffer from the inherent experimental issues associated with T-RFLP and the enormous size and unreliability of many of the sequences in current databases. T-RFLP is most robust when the *in silico* predictions are corroborated with parallel 16S rRNA sequencing (either clone-based or 454 pyrosequencing (Jakobsson et al., 2010)). This is because microbial identification data based solely on *in silico* predictions are not often reliable and can be confusing because of the vast number of possible organisms predicted for each T-RF, many of which suffer from the “uncultured bacterium” phenomenon. Relevant relationships between microbial communities can be assessed by using various tools including principal component analysis, multi-dimensional scaling, self-organizing maps, cluster analysis and canonical correspondence analysis (Schutte et al., 2008).

Certainly, T-RFLP provides invaluable, inexpensive data that can be quite informative with respect to community dynamics particularly if the community members have been characterized using a more sophisticated sequencing-based approach or the identity of specific T-RFs have been determined experimentally. T-RFLP is an excellent tool for measuring the diversity that exists in an amplicon before proceeding to more involved community profiling experiments such as high throughput sequencing.

#### 4.2. Deep sequencing

Nearly 20 different next-generation sequencing instruments are currently on the market (and more are on the way), each with their own advantages and disadvantages (Glenn, 2011). A detailed discussion regarding the technical aspects of all of these technologies is far beyond the scope of this article but excellent resources are available (Martinez and Nelson, 2010; Metzker, 2010). Sequencing experiments can range from 14 days with the Genome Analyzer IIx (Illumina) instrument to a mere two hours with the new Ion Torrent instrument (Life Technologies). Single experiments can generate hundreds of Gigabases of data (Glenn, 2011). Several of the platforms have been widely adopted and include the Roche 454 technology, the Solexa/Illumina platform and Life Technologies SOLiD platform (Metzker, 2010). The incredible amount of sequencing throughput provided by these new instruments has,

for the first time, allowed for a deep characterization of complex microbial communities.

The most common technology that is currently used for community profiling because of the robustness of the chemistry is the 454 FLX Titanium instrument that generates read length of approximately 400 bp with a totally of 500 Mb of data collected in a 10 h run. An upgrade to this instrument can increase the read length to >700 bp and generate 900 Mb of sequence per 18–20 h run. This sequencing by synthesis approach exploits the liberation of pyrophosphate to mediate by the ATP-dependent conversion of luciferin to oxyluciferin. Perhaps the most important advancement in high-throughput sequencing with respect to microbial community profiling has been the advent of barcoding pyrosequencing, which allows for hundreds of microbial communities to be sequenced to exceptional depth simultaneously (Hamady et al., 2008). Barcodes are effectively added to each sequence either by ligation or by amplification with a barcoded primer. There are several different barcoding strategies but it is generally recommended that error-correcting and error-detecting codes should be used (Hamady and Knight, 2009). Fortunately, it appears that different barcode sequences do not significantly alter the community analysis from replicate samples (Hamady et al., 2008; Turnbaugh et al., 2009).

Early versions of pyrosequencing platforms have been shown to be cost effective and improve diagnostic capability in the clinical laboratory particularly for organisms not amenable to biochemical testing (Luna et al., 2007). The ability to generate thousands of sequence reads from hundreds of samples, in a run that takes less than a day, is a very attractive technology for a clinical microbiology laboratory. In fact, significant advances have been made to adapt high-throughput pyrosequencing technology to the clinical laboratory setting and this method has been used to characterize the polymicrobial nature of various clinical entities including rhinosinusitis, surgical wounds and leg ulcers (Wolcott et al., 2009a,b, 2010a,b; Stephenson et al., 2010).

Nucleic acid extraction is perhaps the most important variable in any culture-independent approach to community profiling and high-throughput sequencing is no exception (Morgan et al., 2010). Sequencing data will not accurately correspond to the concentration of community members if the template DNA does not reflect the community composition. It appears that variability between commercially available DNA extraction kits and bead beating in hot phenol may not be tremendously important in terms of species presence/absence but concentration of each community member can vary significantly between extraction protocols (Wu et al., 2010). It is highly advised to rigorously evaluate and validate extraction methods to ensure data accurately reflects community composition (Morgan et al., 2010) before proceeding to costly sequencing efforts and caution must be made in comparing experimental data generated by using different extraction methods (Rogers and Bruce, 2010).

The number of sequence reads that are required from a clinical specimen is dependent on the goal of the study and the nature of the microbial community in the specimen. If broad brush strokes are sought, such as the relative proportion at the phyla-level, shallow sequencing at a level <100 sequence per sample would more than suffice (Ley et al., 2008). However, at a depth of at least 1000 sequences per sample one can confidently infer frequencies of organisms at >1% abundance. If the goal is a complete assessment of all the microbial constituents in a sample, much deeper sequencing may be required and often it is not even possible or practical to accomplish such a task. It has been estimated that if an entire 454 run (1 million reads) was used to for a single fecal sample ( $5 \times 10^5$  sequences) only five cells in every billion total cells would be sampled (Hamady and Knight, 2009). If the goal of a study were to detect rare pathogenic

organisms a targeted PCR approach would obviously be more appropriate.

The 16S rRNA gene is approximately 1.5 Kb and thus is too large to be sequenced in a pyrosequencing reaction and surrogate hyper-variable regions must be used as representatives. There are nine variable regions in the 16S rRNA gene (each vary with respect their utility for microbial identification) and although V2, V4 and V6 provide the lowest error rates when assigning taxonomy (Wang et al., 2007b; Liu et al., 2008), there is currently no standard for which regions to use as a proxy sequence. It has recently been suggested that a combination of V1–V3 and V7–9 might provide better representative characterization (Kumar et al., 2011). Regions V2 and V3 appear to be most effective for universal detection of pathogens (Chakravorty et al., 2007). As with any PCR application, primer selection is critical and primer bias always exists in any community analysis (Walters et al., 2011). However, appreciating what groups of organisms might be disproportionally represented in a given experimental design must be considered. If a metagenomic-based sequencing study was done in parallel to the community profiling, the organisms underrepresented because of PCR bias would not be overlooked (Hamady and Knight, 2009).

An important consideration with all next-generation sequencing technologies is error rate. Error rates are considerably better with the newer GS FLX instrument and can be <1%. The accuracy of next-generation pyrosequencing is comparable to Sanger sequencing (error rates of 0.03–0.07%) when assembly of multiple overlapping sequence reads can be used to correct for sequencing error. This is not possible for community analysis whereby every sequence read represents a distinct organism in the community. Strategies to remove sequences with errors in primer sequence or with read length abnormalities from the data set can significantly improve data quality (Huse et al., 2007). However, care must still be taken to avoid overestimating the diversity in the rare biosphere due to sequencing error (Quince et al., 2009; Reeder and Knight, 2009) and certainly distinguishing low frequency organisms from sequencing error will continue to be an area of intense investigation (Gilles et al., 2011). If the clinical lab is only interested in characterizing the dominant community members, the issues associated with over representing rare organisms would not be an issue because singleton or doubleton reads could be ignored (Petrosino et al., 2009). Chimeric 16S sequences can also be generated during PCR amplification. Software for detecting sequence hybrids exist (Huber et al., 2004; Edgar et al., 2011; Haas et al., 2011) but there has been no entirely effective solutions to deal with this issue in large pyrosequencing data sets.

With respect to 16S rRNA sequence, species, genus and strain-level operational taxonomic units are defined by 95%, 97% and 99% sequence identity, respectively. The most prominent reference databases for 16S rRNA sequence data include Ribosomal Database Project II (RCPII) (Cole et al., 2007), Greengenes (DeSantis et al., 2006) and ARB-SILVA (Pruesse et al., 2007). However, 16S sequencing is not often used in the clinical laboratory for strain-level comparisons because more accurate techniques exist. In a clinical laboratory setting, species level and in some cases strain level determinations are critical for many pathogens. This level of unequivocal taxonomic assignment can, in certain instances, be difficult with 400 bp of 16S rRNA sequence from pyrosequencing and often the most reliable perspective is at genera-level. Confirming specific pathogens by real-time PCR and characterizing them at the strain level by PFGE or MLST could still be required.

Current computational methods including UniFrac (Lozupone and Knight, 2005; Lozupone et al., 2011), SONS (Schloss and Handelsman, 2006), network-based comparisons (Ley et al., 2008) and QIIME (Caporaso et al., 2010) has significantly improved the capacity to analyze large sequence data sets. Hamady and Knight (2009) nicely outline the three major axes for ecological

analysis of microbial diversity from community profiling data: alpha vs. beta diversity, qualitative vs. quantitative analyses and phylogenetic vs. taxon-based analyses (Hamady and Knight, 2009). The type of analysis employed depends entirely on the study design. In a clinical laboratory it is likely that a quantitative, taxon-based, alpha diversity metric would be most appropriate; meaning that a diagnostic platform would measure the concentration and number of taxa in each sample, with an approach that treats all taxa as phylogenetically equivalent entities.

#### 4.3. Other clinical applications of deep sequencing

In addition to bacterial community analysis applications, high-throughput sequencing has been successfully applied to sequencing en masse of total DNA extracted from a microbial community, a technique referred to as metagenomics. The most impressive example of the power of metagenomics to date is the sequencing of nearly 3 million protein coding genes in the fecal metagenome by deep Illumina-based sequencing (Qin et al., 2010). Viral pathogens can also be detected directly using an unbiased metagenomics approach to clinical specimens (Nakamura et al., 2009). During the 2009 H1N1 outbreak there were no laboratory tests initially available to identify the virus and it has been suggested that the virus may have been circulating for months prior to its identification (Smith et al., 2009). Metagenomics was capable of detecting the influenza virus at titers near the limit of detection of RT-PCR (Greninger et al., 2010). This approach could play an important role in rapid detection of other novel pathogens during outbreaks of acute, unexplained illness (Tang and Chiu, 2010). It has already been applied to the diagnosis of lymphocytic choriomeningitis virus infection in transplant recipients (Palacios et al., 2008), in addition to defining the etiology of hemorrhagic fever outbreaks (Towner et al., 2008; Briese et al., 2009).

Bacterial genome sequencing, originally an extremely labor intensive and time consuming process, could realistically become a routine tool in diagnostics, epidemiology and infection control (Pallen et al., 2010). When no reference genome exists, 454-based pyrosequencing is best suited for de novo assembly due to the long read lengths; however, platforms that output shorter reads are suitable if a scaffold genome is available. The anthrax attacks of 2001 highlight the need for rapid bacterial genome sequencing. 454-based pyrosequencing technology was shown to be capable of generating a draft genome of *Bacillus anthracis* that could be used to assess relevant genetic variants in less than 24 h (Chen et al., 2010). More recently, the genome of the *E. coli* isolate implicated in the outbreak in Europe was completely sequenced in the matter of a few hours using the Ion Torrent platform. Sequencing a bacterial genome is no longer expensive and it has been estimated that a Streptococcal genome with greater than 150-fold coverage can cost as little as US\$100 (Vernet et al., 2011). Whole genome sequencing has great value as an epidemiologic tool and was recently shown to be superior to the gold standard typing method, PFGE, during a recent Canadian *Listeria monocytogenes* outbreak (Gilmour et al., 2010). Similar observations have been made with multi-drug resistant *Acinetobacter baumannii* (Lewis et al., 2010). Genome wide SNP analysis is an extremely discriminating tool for studying transmission events and could be adopted by the clinical laboratory for routine and outbreak surveillance. Such approaches have generated an insightful perspective on the epidemiology of epidemics including the important community and hospital pathogen, methicillin-resistant *S. aureus* (MRSA) (Harris et al., 2010) and Group A *Streptococcus* (Beres et al., 2010). In addition to epidemiology applications, whole genome sequencing can also be effective for defining antibiotic resistance determinants of a particular pathogen, such as linezolid resistance in *Streptococcus pneumoniae* (Feng et al., 2009). Technology now

exists for whole genome sequencing from single bacterial cells, which relies on multiple displacement amplification (Rodrigue et al., 2009; Woyke et al., 2010). It will be most interesting to see how such approaches are used to characterize rare, enigmatic members of the human microbiome.

There are several considerations as sequencing technologies continue to significantly improve output and begin to transition into the clinical laboratory. There is a real need to streamline the bioinformatics such that a technician in the clinical laboratory can manipulate deep sequencing data. The vast amounts of data that a clinical lab would produce are staggering and the computational infrastructure would require significant improvement, which would likely require taking advantage of distributed computing and robust server networks (Petrosino et al., 2009). For community profiling in clinical samples further data is required to indicate the precise clinically relevant biomarkers that predict the pathogenic potential of communities or are effective in disease risk management, before such approaches are commonplace. There are also several technical aspects that need to be resolved before a clear clinical application can be realized. For example, human-associated microbial communities contain both live and dead bacteria and PCR cannot distinguish between these two sources of nucleic acid. The protocol development in this regard has been exciting (Rogers et al., 2008; Nocker and Camper, 2009) but further validation in the high throughput sequencing pipeline is required (Rogers and Bruce, 2010).

## 5. Future directions

Although larger clinical microbiology laboratories are increasingly developing their own molecular assays and procedures in-house, several barriers exist in this process including rigorous validation for the population being tested, quality control, ensuring a high degree of automation, access to dedicated technologists who are trained and experienced in molecular techniques, access to capital to purchase the necessary equipment, and the expense of operating a molecular microbiology laboratory alongside the phenotypic culture-dependent testing. However, implementation of culture-independent testing methods in clinical microbiology will increase over the next decade not only due to the continued development of multiplexing methods (real-time PCR, liquid suspension bead-based arrays) but also due to improvements in future generations of sequencing platforms that increase capacity and read length while reducing cost (Martinez and Nelson, 2010). High-throughput sequencing technologies appear to be following Moore's law and increasingly the potential applications to clinical microbiology will become more apparent (Pallen et al., 2010). For example, in addition to the bacterial community analysis, deep sequencing has been applied to viral communities in the human body. Deep sequencing of intra-patient HIV viral genomes has revealed an intriguing perspective on viral resistance and ecology (Wang et al., 2007a; Eriksson et al., 2008; Le et al., 2009; Simen et al., 2009). One can envision the next generation of clinical microbiologists having the ability to perform complex analyses as diagnostic and epidemiological tools such as routine genome wide SNPs, high throughput community analysis and streamlined metagenomic testing for novel pathogen discovery within a reasonable clinical turnaround time. However, although the clinical microbiology diagnostic techniques 'tool-box' has the potential to significantly increase in the future, it is very unlikely that culture-independent approaches will entirely replace cultivation of microbes because of the importance of strain stocks and phenotypic information is not easily inferred from genotypic data.

As medical management of infectious diseases evolves so too will the need for alternate perspectives on complex chronic

infections. In future, molecular approaches may also be routinely used to simultaneously investigate host susceptibility for particular types of infection, as well as determine pathogen induced phenotypic changes in host gene expression during microbial infections that prognosticate clinical outcome.

## References

- Abdo, Z., Schuette, U.M., et al., 2006. Statistical methods for characterizing diversity of microbial communities by analysis of terminal restriction fragment length polymorphisms of 16S rRNA genes. *Environ. Microbiol.* 8 (5), 929–938.
- Albrecht, V., Chevallier, A., et al., 2006. Easy and fast detection and genotyping of high-risk human papillomavirus by dedicated DNA microarrays. *J. Virol. Methods* 137, 236–244.
- Ammann, R.A., Zucol, F., et al., 2007. Real-time broad-range PCR versus blood culture. A prospective pilot study in pediatric cancer patients with fever and neutropenia. *Support. Care Cancer* 15 (6), 637–641.
- Atkins, S.D., Clark, I.M., 2004. Fungal molecular diagnostics: a mini review. *J. Appl. Genet.* 45 (1), 3–15.
- Babouee, B., Frei, R., 2011. Comparison of the DiversiLab repetitive element PCR system with spa typing and pulsed-field gel electrophoresis for clonal characterization of methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* 49 (4), 1549–1555.
- Bager, F., Aarestrup, F.M., et al., 1999. Design of a system for monitoring antimicrobial resistance in pathogenic, zoonotic and indicator bacteria from food animals. *Acta Vet. Scand. Suppl.* 92, 77–86.
- Baker, G.C., Smith, J.J., et al., 2003. Review and re-analysis of domain-specific 16S primers. *J. Microbiol. Methods* 55 (3), 541–555.
- Baldwin, C.D., Howe, G.B., et al., 2009. Usefulness of multilocus polymerase chain reaction followed by electrospray ionization mass spectrometry to identify a diverse panel of bacterial isolates. *Diagn. Microbiol. Infect. Dis.* 63 (4), 403–408.
- Barken, K.B., Haagensen, J.A., et al., 2007. Advances in nucleic acid-based diagnostics of bacterial infections. *Clin. Chim. Acta* 384 (1–2), 1–11.
- Beadle, J., Wright, M., et al., 2003. Electrophoretic karyotype analysis in fungi. *Adv. Appl. Microbiol.* 53, 243–270.
- Beres, S.B., Carroll, R.K., et al., 2010. Molecular complexity of successive bacterial epidemics deconvoluted by comparative pathogenomics. *Proc. Natl. Acad. Sci. USA* 107 (9), 4371–4376.
- Bik, E.M., Eckburg, P.B., et al., 2006. Molecular analysis of the bacterial microbiota in the human stomach. *Proc. Natl. Acad. Sci. USA* 103 (3), 732–737.
- Blake, D.R., Doherty, L.F., 2006. Effect of perineal cleansing on contamination rate of mid-stream urine culture. *J. Pediatr. Adolesc. Gynecol.* 19 (1), 31–34.
- Blyn, L.B., Hall, T.A., et al., 2008. Rapid detection and molecular serotyping of adenovirus by use of PCR followed by electrospray ionization mass spectrometry. *J. Clin. Microbiol.* 46 (2), 644–651.
- Borman, A.M., Linton, C.J., et al., 2008. Molecular identification of pathogenic fungi. *J. Antimicrob. Chemother.* 61 (Suppl 1), i7–12.
- Borman, A.M., Linton, C.J., et al., 2010. Rapid molecular identification of pathogenic yeasts by pyrosequencing analysis of 35 nucleotides of internal transcribed spacer 2. *J. Clin. Microbiol.* 48 (10), 3648–3653.
- Bosshard, P.P., Abels, S., et al., 2004. Comparison of conventional and molecular methods for identification of aerobic catalase-negative gram-positive cocci in the clinical laboratory. *J. Clin. Microbiol.* 42 (5), 2065–2073.
- Bosshard, P.P., Abels, S., et al., 2003a. Ribosomal DNA sequencing for identification of aerobic gram-positive rods in the clinical laboratory (an 18-month evaluation). *J. Clin. Microbiol.* 41 (9), 4134–4140.
- Bosshard, P.P., Kronenberg, A., et al., 2003b. Etiologic diagnosis of infective endocarditis by broad-range polymerase chain reaction: a 3-year experience. *Clin. Infect. Dis.* 37 (2), 167–172.
- Bosshard, P.P., Zbinden, R., et al., 2006. 16S rRNA gene sequencing versus the API 20 NE system and the VITEK 2 ID-GNB card for identification of nonfermenting Gram-negative bacteria in the clinical laboratory. *J. Clin. Microbiol.* 44 (4), 1359–1366.
- Bottger, E.C., 1989. Rapid determination of bacterial ribosomal RNA sequences by direct sequencing of enzymatically amplified DNA. *FEMS Microbiol. Lett.* 53 (1–2), 171–176.
- Bottger, E.C., Teske, A., et al., 1992. Disseminated “*Mycobacterium genavense*” infection in patients with AIDS. *Lancet* 340 (8811), 76–80.
- Bourdon, N., Lemire, A., et al., 2011. Comparison of four methods, including semi-automated rep-PCR, for typing of vancomycin-resistant *Enterococcus faecium*. *J. Microbiol. Methods* 84 (1), 74–80.
- Breitkopf, C., Hammel, D., et al., 2005. Impact of a molecular approach to improve the microbiological diagnosis of infective heart valve endocarditis. *Circulation* 111 (11), 1415–1421.
- Briese, T., Paweska, J.T., et al., 2009. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. *PLoS Pathog.* 5 (5), e1000455.
- Brolund, A., Haeggman, S., et al., 2010. The DiversiLab system versus pulsed-field gel electrophoresis: characterisation of extended spectrum B-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. *J. Microbiol. Methods* 83 (2), 224–230.
- Brook, I., 1999. Bacterial interference. *Crit. Rev. Microbiol.* 25 (3), 155–172.
- Caporaso, J.G., Kuczynski, J., et al., 2010. QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* 7 (5), 335–336.
- Caram, L.B., Linefsky, J.P., et al., 2008. *Leptotrichia endocarditis*: report of two cases from the International Collaboration on Endocarditis (ICE) database and review of previous cases. *Eur. J. Clin. Microbiol. Infect. Dis.* 27 (2), 139–143.
- Chakravorty, S., Helb, D., et al., 2007. A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. *J. Microbiol. Methods* 69 (2), 330–339.
- Chaloner, G.L., Harrison, T.G., et al., 2011. Multilocus sequence typing of *Bartonella henselae* in the United Kingdom indicates that only a few, uncommon sequence types are associated with zoonotic disease. *J. Clin. Microbiol.* 49 (6), 2132–2137.
- Chang, S.S., Hsu, H.L., et al., 2011. An efficient strategy for broad-range detection of low abundance bacteria without DNA decontamination of PCR reagents. *PLoS ONE* 6 (5), e20303.
- Chapman, L.E., Khabbaz, R.F., 1994. Etiology and epidemiology of the Four Corners hantavirus outbreak. *Infect. Agents Dis.* 3 (5), 234–244.
- Chen, K.F., Blyn, L., et al., 2011a. Reverse transcription polymerase chain reaction and electrospray ionization mass spectrometry for identifying acute viral upper respiratory tract infections. *Diagn. Microbiol. Infect. Dis.* 69 (2), 179–186.
- Chen, K.F., Rothman, R.E., et al., 2011b. Rapid identification viruses from nasal pharyngeal aspirates in acute viral respiratory infections by RT-PCR and electrospray ionization mass spectrometry. *J. Virol. Methods* 173 (1), 60–66.
- Chen, P.E., Willner, K.M., et al., 2010. Rapid identification of genetic modifications in *Bacillus anthracis* using whole genome draft sequences generated by 454 pyrosequencing. *PLoS ONE* 5 (8), e12397.
- Cho, E.J., Do, J.H., et al., 2011. Evaluation of a liquid bead array system for high-risk human papillomavirus detection and genotyping and comparison with Hybrid Capture II, DNA chip and sequencing methods. *J. Med. Microbiol.* 66 (1), 62–71.
- Choo, Q.L., Kuo, G., et al., 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244 (4902), 359–362.
- Chuang, Y.C., Wang, J.T., et al., 2010. Comparison of an automated repetitive-sequence-based PCR microbial typing system with pulsed-field gel electrophoresis for molecular typing of vancomycin-resistant *Enterococcus faecium*. *J. Clin. Microbiol.* 48 (8), 2897–2901.
- Church, D.L., 2004. Major factors affecting the emergence and re-emergence of infectious diseases. *Clin. Lab. Med.* 24 (3), 559–586.
- Church, D.L., Chow, B.L., et al., 2011a. Comparison of automated repetitive-sequence-based polymerase chain reaction and spa typing versus pulsed-field gel electrophoresis for molecular typing of methicillin-resistant *Staphylococcus aureus*. *Diagn. Microbiol. Infect. Dis.* 69 (1), 30–37.
- Church, D.L., Chow, B.L., et al., 2011b. Evaluation of automated repetitive-sequence-based PCR (DiversiLab) compared to PCR ribotyping for rapid molecular typing of community- and nosocomial-acquired *Clostridium difficile*. *Diagn. Microbiol. Infect. Dis.* 70 (2), 183–190.
- Ciardo, D.E., Lucke, K., et al., 2010. Systematic internal transcribed spacer sequence analysis for identification of clinical mold isolates in diagnostic mycology: a 5-year study. *J. Clin. Microbiol.* 48 (8), 2809–2813.
- Ciardo, D.E., Schar, G., et al., 2007. Identification of moulds in the diagnostic laboratory – an algorithm implementing molecular and phenotypic methods. *Diagn. Microbiol. Infect. Dis.* 59 (1), 49–60.
- Clarke, T.B., Davis, K.M., et al., 2010. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. *Nat. Med.* 16 (2), 228–231.
- Cole, J.R., Chai, B., et al., 2007. The ribosomal database project (RDP-II): introducing myRDP space and quality controlled public data. *Nucleic Acids Res.* 35 (Database issue), D169–D172.
- Collins, R.E., Rocap, G., 2007. REPK: an analytical web server to select restriction endonucleases for terminal restriction fragment length polymorphism analysis. *Nucleic Acids Res.* 35 (Web Server issue), W58–W62.
- Compton, J., 1991. Nucleic acid sequence-based amplification. *Nature* 350 (6313), 91–92.
- Coolen, M.J., Post, E., et al., 2005. Characterization of microbial communities found in the human vagina by analysis of terminal restriction fragment length polymorphisms of 16S rRNA genes. *Appl. Environ. Microbiol.* 71 (12), 8729–8737.
- Corless, C.E., Guiver, M., et al., 2000. Contamination and sensitivity issues with a real-time universal 16S rRNA PCR. *J. Clin. Microbiol.* 38 (5), 1747–1752.
- Croagh, C.M., Bell, S.J., et al., 2010. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. *Liver Int.* 30 (8), 1115–1122.
- Davies, J., 2001. In a map for human life, count the microbes, too. *Science* 291 (5512), 2316.
- Dawood, F.S., Jain, S., et al., 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. *N. Engl. J. Med.* 360 (25), 2605–2615.
- Deplano, A., Denis, O., et al., 2011. Controlled performance evaluation of DiversiLab repetitive-sequence-based genotyping system for typing multidrug-resistant health care-associated bacterial pathogens. *J. Clin. Microbiol.* 49 (10), 3616–3620.
- DeSantis, T.Z., Hugenholtz, P., et al., 2006. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Appl. Environ. Microbiol.* 72 (7), 5069–5072.
- Deutch, S., Dahlberg, D., et al., 2007. Diagnosis of ventricular drainage-related bacterial meningitis by broad-range real-time polymerase chain reaction. *Neurosurgery* 61 (2), 306–311 (discussion 311–302).
- Deyde, V.M., Sampath, R., et al., 2010. Genomic signature-based identification of influenza A viruses using RT-PCR/electrospray ionization mass spectrometry (ESI-MS) technology. *PLoS ONE* 5 (10), e13293.
- Dhillon, R.H., Clark, J., et al., 2009. Reducing blood culture contamination. *J. Hosp. Infect.* 73 (1), 97–99.

- Diene, S.M., Bruder, N., et al., 2011. Real-time PCR assay allows detection of the New Delhi metallo-beta-lactamase (NDM-1)-encoding gene in France. *Int. J. Antimicrob. Agents* 37 (6), 544–546.
- Doolittle, W.F., 1999. Phylogenetic classification and the universal tree. *Science* 284 (5423), 2124–2129.
- Drancourt, M., Bollet, C., et al., 2000. 16S ribosomal DNA sequence analysis of a large collection of environmental and clinical unidentifiable bacterial isolates. *J. Clin. Microbiol.* 38 (10), 3623–3630.
- Dreier, J., Vollmer, T., et al., 2008. Culture-negative infectious endocarditis caused by *Bartonella* spp.: 2 case reports and a review of the literature. *Diagn. Microbiol. Infect. Dis.* 61 (4), 476–483.
- Drosten, C., Gunther, S., et al., 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N. Engl. J. Med.* 348 (20), 1967–1976.
- Dunbar, J., Ticknor, L.O., et al., 2001. Phylogenetic specificity and reproducibility and new method for analysis of terminal restriction fragment profiles of 16S rRNA genes from bacterial communities. *Appl. Environ. Microbiol.* 67 (1), 190–197.
- Ecker, D.J., Sampath, R., et al., 2008. Ibis T5000: a universal biosensor approach for microbiology. *Nat. Rev. Microbiol.* 6 (7), 553–558.
- Edberg, A., Jurstrand, M., et al., 2008. A comparative study of three different PCR assays for detection of *Mycoplasma genitalium* in urogenital specimens from men and women. *J. Med. Microbiol.* 57 (Pt 3), 304–309.
- Edgar, R.C., Haas, B.J., et al., 2011. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics*.
- Eklund, C., Zhou, T., et al., 2010. Global proficiency study of human papillomavirus genotyping. *J. Clin. Microbiol.* 48 (11), 4147–4155.
- Engbretson, J.J., Moyer, C.L., 2003. Fidelity of select restriction endonucleases in determining microbial diversity by terminal-restriction fragment length polymorphism. *Appl. Environ. Microbiol.* 69 (8), 4823–4829.
- Eriksson, N., Pachter, L., et al., 2008. Viral population estimation using pyrosequencing. *PLoS Comput. Biol.* 4 (4), e1000074.
- Ermel, A., Qadadri, B., et al., 2010. Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the Digene Hybrid Capture II assay, the Roche Linear Array HPV genotyping assay, and the Kurabo GeneSquare microarray assay. *J. Virol. Methods* 169, 154–161.
- Eshoo, M.W., Crowder, C.D., et al., 2010. Detection and identification of Ehrlichia species in blood by use of PCR and electrospray ionization mass spectrometry. *J. Clin. Microbiol.* 48 (2), 472–478.
- Eshoo, M.W., Whitehouse, C.A., et al., 2009. Rapid and high-throughput pan-Orthopoxvirus detection and identification using PCR and mass spectrometry. *PLoS ONE* 4 (7), e6342.
- Espy, M.J., Uhl, J.R., et al., 2006. Real-time PCR in clinical microbiology: applications for routine laboratory testing. *Clin. Microbiol. Rev.* 19 (1), 165–256.
- Facklam, R., 2002. What happened to the streptococci: overview of taxonomic and nomenclature changes. *Clin. Microbiol. Rev.* 15 (4), 613–630.
- Fahy, E., Kwoh, D.Y., et al., 1991. Self-sustained sequence replication (3SR): an isothermal transcription-based amplification system alternative to PCR. *PCR Methods Appl.* 1 (1), 25–33.
- Falk, E.S., Danielsson, D., et al., 1985. Genomic fingerprinting in the epidemiology of gonorrhoea. *Acta Derm. Venereol.* 65 (3), 235–239.
- Farrar Jr., W.E., 1983. Molecular analysis of plasmids in epidemiologic investigation. *J. Infect. Dis.* 148 (1), 1–6.
- Feng, J., Lupien, A., et al., 2009. Genome sequencing of linezolid-resistant *Streptococcus pneumoniae* mutants reveals novel mechanisms of resistance. *Genome Res.* 19 (7), 1214–1223.
- Fenollar, F., Gauduchon, V., et al., 2004. *Mycoplasma endocarditis*: two case reports and a review. *Clin. Infect. Dis.* 38 (3), e21–24.
- Fenollar, F., Laouira, S., et al., 2008a. Value of *Tropheryma whippelii* quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. *Clin. Infect. Dis.* 47 (5), 659–667.
- Fenollar, F., Levy, P.Y., et al., 2008b. Usefulness of broad-range PCR for the diagnosis of osteoarticular infections. *Curr. Opin. Rheumatol.* 20 (4), 463–470.
- Fenollar, F., Raoult, D., 2004. Molecular genetic methods for the diagnosis of fastidious microorganisms. *APMIS* 112 (11–12), 785–807.
- Fenollar, F., Raoult, D., 2007. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. *Int. J. Antimicrob. Agents* 30 (Suppl 1), S7–S15.
- Fenollar, F., Roux, V., et al., 2006. Analysis of 525 samples to determine the usefulness of PCR amplification and sequencing of the 16S rRNA gene for diagnosis of bone and joint infections. *J. Clin. Microbiol.* 44 (3), 1018–1028.
- Fisher, M.M., Triplett, E.W., 1999. Automated approach for ribosomal intergenic spacer analysis of microbial diversity and its application to freshwater bacterial communities. *Appl. Environ. Microbiol.* 65 (10), 4630–4636.
- Fitzgerald, C., Collins, M., et al., 2007. Multiplex, bead-based suspension array for molecular determination of common *Salmonella* serogroups. *J. Clin. Microbiol.* 45 (10), 3323–3334.
- Fluit, A.C., Terlingen, A.M., et al., 2010. Evaluation of DiversiLab system for detection of hospital outbreaks of infections by different bacteria. *J. Clin. Microbiol.* 48 (11), 3979–3989.
- Fournier, P.E., Drancourt, M., et al., 2007. Bacterial genome sequencing and its use in infectious diseases. *Lancet Infect. Dis.* 7 (11), 711–723.
- Fournier, P.E., Raoult, D., 2007. Identification of rickettsial isolates at the species level using multi-spacer typing. *BMC Microbiol.* 7, 72.
- Fournier, P.E., Raoult, D., 2011. Prospects for the Future Using Genomics and Proteomics in Clinical Microbiology. *Annu. Rev. Microbiol.* 65, 169–188.
- Fournier, P.E., Thuny, F., et al., 2010. Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. *Clin. Infect. Dis.* 51 (2), 131–140.
- Francois, P., Huyghe, A., et al., 2005. Use of an automated multiple-locus, variable-number tandem repeat-based method for rapid and high-throughput genotyping of *Staphylococcus aureus* isolates. *J. Clin. Microbiol.* 43 (7), 3346–3355.
- Gheit, T., Landi, S., et al., 2006. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. *J. Clin. Microbiol.* 44 (6), 2025–2031.
- Gilles, A., Meglec, E., et al., 2011. Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. *BMC Genomics* 12, 245.
- Gilmour, M.W., Graham, M., et al., 2010. High-throughput genome sequencing of two *Listeria monocytogenes* clinical isolates during a large foodborne outbreak. *BMC Genomics* 11, 120.
- Glenn, T.C., 2011. Field guide to next-generation DNA sequencers. *Mol. Ecol. Resour.*
- Goering, R.V., 2010. Pulsed field gel electrophoresis: a review of application and interpretation in the molecular epidemiology of infectious disease. *Infect. Genet. Evol.* 10 (7), 866–875.
- Goh, S.H., Byrne, S.K., et al., 1992. Molecular typing of *Staphylococcus aureus* on the basis of coagulase gene polymorphisms. *J. Clin. Microbiol.* 30 (7), 1642–1645.
- Goldschmidt, P., Rostane, H., et al., 2006. Detection by broad-range real-time PCR assay of Chlamydia species infecting human and animals. *Br. J. Ophthalmol.* 90 (11), 1425–1429.
- Gouriet, F., Fenollar, F., et al., 2005. Use of shell-vial cell culture assay for isolation of bacteria from clinical specimens: 13 years of experience. *J. Clin. Microbiol.* 43 (10), 4993–5002.
- Grahn, N., Olofsson, M., et al., 2003. Identification of mixed bacterial DNA contamination in broad-range PCR amplification of 16S rDNA V1 and V3 variable regions by pyrosequencing of cloned amplicons. *FEMS Microbiol. Lett.* 219 (1), 87–91.
- Greisen, K., Loeffelholz, M., et al., 1994. PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid. *J. Clin. Microbiol.* 32 (2), 335–351.
- Greninger, A.L., Chen, E.C., et al., 2010. A metagenomic analysis of pandemic influenza A (2009 H1N1) infection in patients from North America. *PLoS ONE* 5 (10), e13381.
- Greub, G., Lepidi, H., et al., 2005. Diagnosis of infectious endocarditis in patients undergoing valve surgery. *Am. J. Med.* 118 (3), 230–238.
- Gu, Z., Hall, T.A., et al., 2011. Evaluation of repetitive sequence PCR and PCR-mass spectrometry for the identification of clinically relevant *Candida* species. *Med. Mycol.* 118.
- Haas, B.J., Gevers, D., et al., 2011. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. *Genome Res.* 21 (3), 494–504.
- Hadfield, S.J., Robinson, G., et al., 2011. Detection and differentiation of *Cryptosporidium* spp. in human clinical samples by use of real-time PCR. *J. Clin. Microbiol.* 49 (3), 918–924.
- Hall, T.A., Sampath, R., et al., 2009. Rapid molecular genotyping and clonal complex assignment of *Staphylococcus aureus* isolates by PCR coupled to electrospray ionization-mass spectrometry. *J. Clin. Microbiol.* 47 (6), 1733–1741.
- Hamady, M., Knight, R., 2009. Microbial community profiling for human microbiome projects: tools, techniques, and challenges. *Genome Res.* 19 (7), 1141–1152.
- Hamady, M., Walker, J.J., et al., 2008. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. *Nat. Methods* 5 (3), 235–237.
- Hansen, D., Healy, M., et al., 2008. Repetitive-sequence-based PCR using the DiversiLab system for identification of *Aspergillus* species. *J. Clin. Microbiol.* 46 (5), 1835–1839.
- Harmsen, D., Claus, H., et al., 2003a. Typing of methicillin-resistant *Staphylococcus aureus* in a university hospital setting by using novel software for spa repeat determination and database management. *J. Clin. Microbiol.* 41 (12), 5442–5448.
- Harmsen, D., Dostal, S., et al., 2003b. RIDOM: comprehensive and public sequence database for identification of *Mycobacterium* species. *BMC Infect. Dis.* 3, 26.
- Harris, K.A., Hartley, J.C., 2003. Development of broad-range 16S rDNA PCR for use in the routine diagnostic clinical microbiology service. *J. Med. Microbiol.* 52 (Pt 8), 685–691.
- Harris, S.R., Feil, E.J., et al., 2010. Evolution of MRSA during hospital transmission and intercontinental spread. *Science* 327 (5964), 469–474.
- Hayford, A.E., Mammel, M.K., et al., 2011. Single nucleotide polymorphism (SNP)-based differentiation of *Shigella* isolates by pyrosequencing. *Infect. Genet. Evol.*
- Healy, M., Huang, J., et al., 2005. Microbial DNA typing by automated repetitive-sequence-based PCR. *J. Clin. Microbiol.* 43 (1), 199–207.
- Heid, C.A., Stevens, J., et al., 1996. Real time quantitative PCR. *Genome Res.* 6 (10), 986–994.
- Heikens, E., Fleer, A., et al., 2005. Comparison of genotypic and phenotypic methods for species-level identification of clinical isolates of coagulase-negative staphylococci. *J. Clin. Microbiol.* 43 (5), 2286–2290.
- Higgins, P.G., Hujer, A.M., et al., 2012. Interlaboratory reproducibility of DiversiLab rep-PCR typing and clustering of *Acinetobacter baumannii* isolates. *J. Clin. Microbiol.* 61 (Pt. 1), 137–141.
- Heymans, R., van der Helm, J.J., et al., 2010. Clinical value of *Treponema pallidum* real-time PCR for diagnosis of syphilis. *J. Clin. Microbiol.* 48 (2), 497–502.

- Hofstadler, S.A., S. R., Blyn, L.R., Eshoo, M.W., Hall, T.A., Jiang, Y., Drader, J.J., Hannis, J.C., Sannes-Lowery, K.A., Cummins, L.L., Libby, B., Walcott, D.J., Schink, A., Massire, C., Ranken, R., Gutierrez, J., Manalili, S., Ivy, C., Melton, R., Levene, H., Barrett-Wilt, G., Li, F., Zapp, V., White, N., Saant, V., McNeil, J.A., Knize, D., Robbins, D., Rudnick, K., Desai, A., Moradi, E., Ecker, D.J., 2005. TIGER: the universal biosensor. *Int. J. Mass. Spectrom.* 242, 23–41.
- Hooper, L.V., 2004. Bacterial contributions to mammalian gut development. *Trends Microbiol.* 12 (3), 129–134.
- Houpikian, P., Raoult, D., 2005. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. *Medicine (Baltimore)* 84 (3), 162–173.
- Huang, Y.Q., Li, J.J., et al., 1995. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. *Lancet* 345 (8952), 759–761.
- Huber, T., Faulkner, G., et al., 2004. Bellerophon: a program to detect chimeric sequences in multiple sequence alignments. *Bioinformatics* 20 (14), 2317–2319.
- Huse, S.M., Huber, J.A., et al., 2007. Accuracy and quality of massively parallel DNA pyrosequencing. *Genome Biol.* 8 (7), R143.
- Hwang, T.S., Jeong, J.K., et al., 2003. Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray. *Gynecol. Oncol.* 90 (1), 51–56.
- Ishikawa, H., Kutsukake, E., et al., 2011. The performance of the BD geneOhm MRSA assay for MRSA isolated from clinical patients in Japan, including the effects of specimen contamination and ways to improve it. *J. Infect. Chemother.* 17 (2), 214–218.
- Issartel, B., Gauduchon, V., et al., 2002. Clinically and histologically silent Q fever endocarditis accidentally diagnosed by PCR. *Clin. Microbiol. Infect.* 8 (2), 113–114.
- Itakura, J., Asahina, Y., et al., 2011. Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. *Hepatology* 53 (3), 217–224.
- Jakobsson, H.E., Jernberg, C., et al., 2010. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. *PLoS ONE* 5 (3), e9836.
- Janda, J.M., Abbott, S.L., 2002. Bacterial identification for publication: when is enough enough? *J. Clin. Microbiol.* 40 (6), 1887–1891.
- Jordan, J.A., Butchko, A.R., et al., 2005. Use of pyrosequencing of 16S rRNA fragments to differentiate between bacteria responsible for neonatal sepsis. *J. Mol. Diagn.* 7 (1), 105–110.
- Kaewpongsri, S., Sukasem, C., et al., 2010. An integrated bioinformatics approach to the characterization of influenza A/H5N1 viral sequences by microarray data: Implication for monitoring H5N1 emerging strains and designing appropriate influenza vaccines. *Mol. Cell. Probes* 24 (6), 387–395.
- Kaleta, E.J., Clark, A.E., et al., 2011. Use of PCR coupled with electrospray ionization mass spectrometry for rapid identification of bacterial and yeast bloodstream pathogens from blood culture bottles. *J. Clin. Microbiol.* 49 (1), 345–353.
- Kaplan, C.W., Kitts, C.L., 2003. Variation between observed and true Terminal Restriction Fragment length is dependent on true TRF length and purine content. *J. Microbiol. Methods* 54 (1), 121–125.
- Kent, A.D., Smith, D.J., et al., 2003. Web-based phylogenetic assignment tool for analysis of terminal restriction fragment length polymorphism profiles of microbial communities. *Appl. Environ. Microbiol.* 69 (11), 6768–6776.
- Klug, S.J., Molijs, A., et al., 2008. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. *J. Med. Virol.* 80, 1264–1274.
- Kobayashi, N., Bauer, T.W., et al., 2005. A molecular gram stain using broad range PCR and pyrosequencing technology: a potentially useful tool for diagnosing orthopaedic infections. *Diagn. Mol. Pathol.* 14 (2), 83–89.
- Koessler, T., Francois, P., et al., 2006. Use of oligoarrays for characterization of community-onset methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* 44 (3), 1040–1048.
- Kremer, K., Arnold, C., et al., 2005. Discriminatory power and reproducibility of novel DNA typing methods for *Mycobacterium tuberculosis* complex strains. *J. Clin. Microbiol.* 43 (11), 5628–5638.
- Kronic, N., Yager, T.D., et al., 2007. XTAG RVP assay: analytical and clinical performance. *J. Clin. Virol.* 40 (Suppl 1), S39–46.
- Kruttgen, A., Razavi, S., et al., 2011. Real-time PCR assay and a synthetic positive control for the rapid and sensitive detection of the emerging resistance gene New Delhi Metallo-beta-lactamase-1 (bla(NDM-1)). *Med. Microbiol. Immunol.* 200 (2), 137–141.
- Ksiazek, T.G., Erdman, D., et al., 2003. A novel coronavirus associated with severe acute respiratory syndrome. *N. Engl. J. Med.* 348 (20), 1953–1966.
- Kumar, P.S., Brooker, M.R., et al., 2011. Target region selection is a critical determinant of community fingerprints generated by 16S pyrosequencing. *PLoS ONE* 6 (6), e20956.
- Kuo, C.C., Jackson, L.A., et al., 1995. *Chlamydia pneumoniae* (TWAR). *Clin. Microbiol. Rev.* 8 (4), 451–461.
- Kurtzman, C.P., Robnett, C.J., 1997. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5' end of the large-subunit (26S) ribosomal DNA gene. *J. Clin. Microbiol.* 35 (5), 1216–1223.
- Kwoh, D.Y., Davis, G.R., et al., 1989. Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. *Proc. Natl. Acad. Sci. USA* 86 (4), 1173–1177.
- Le, T., Chiarella, J., et al., 2009. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. *PLoS ONE* 4 (6), e6079.
- Lehours, P., Freydiere, A.M., et al., 2011. The rtxA toxin gene of *Kingella kingae*: a pertinent target for molecular diagnosis of osteoarticular infections. *J. Clin. Microbiol.* 49 (4), 1245–1250.
- Lepidi, H., Fenollar, F., et al., 2004. Cardiac valves in patients with *Whipple endocarditis*: microbiological, molecular, quantitative histologic, and immunohistochemical studies of 5 patients. *J. Infect. Dis.* 190 (5), 935–945.
- Lepidi, H., Houpikian, P., et al., 2003. Cardiac valves in patients with Q fever endocarditis: microbiological, molecular, and histologic studies. *J. Infect. Dis.* 187 (7), 1097–1106.
- Lewis, T., Loman, N.J., et al., 2010. High-throughput whole-genome sequencing to dissect the epidemiology of *Acinetobacter baumannii* isolates from a hospital outbreak. *J. Hosp. Infect.* 75 (1), 37–41.
- Ley, R.E., Hamady, M., et al., 2008. Evolution of mammals and their gut microbes. *Science* 320 (5883), 1647–1651.
- Ley, R.E., Peterson, D.A., et al., 2006. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell* 124 (4), 837–848.
- Li, N., Franceschi, S., et al., 2011. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. *Int. J. Cancer* 128, 927–935.
- Li, M., Wang, B., et al., 2008. Symbiotic gut microbes modulate human metabolic phenotypes. *Proc. Natl. Acad. Sci. USA* 105 (6), 2117–2122.
- Lilliebridge, R.A., Tong, S.Y., et al., 2011. The utility of high-resolution melting analysis of SNP nucleated PCR amplicons—an MLST based *Staphylococcus aureus* typing scheme. *PLoS ONE* 6 (6), e19749.
- Lisby, G., 1998. Application of nucleic acid amplification in clinical microbiology. *Methods Mol. Biol.* 92, 1–29.
- Liu, W.T., Marsh, T.L., et al., 1997. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. *Appl. Environ. Microbiol.* 63 (11), 4516–4522.
- Liu, Z., DeSantis, T.Z., et al., 2008. Accurate taxonomy assignments from 16S rRNA sequences produced by highly parallel pyrosequencers. *Nucleic Acids Res.* 36 (18), e120.
- Loewe, R.P., Nelson, P.J., 2011. Microarray bioinformatics. *Methods Mol. Biol.* 671, 295–320.
- Lozupone, C., Knight, R., 2005. UniFrac: a new phylogenetic method for comparing microbial communities. *Appl. Environ. Microbiol.* 71 (12), 8228–8235.
- Lozupone, C., Lladser, M.E., et al., 2011. UniFrac: an effective distance metric for microbial community comparison. *ISME J.* 5 (2), 169–172.
- Luft, L.M., Gill, M.J., et al., 2011. HIV-1 viral diversity and its implications for viral load testing: review of current platforms. *Int. J. Infect. Dis.*
- Luna, R.A., Fasciano, L.R., et al., 2007. DNA pyrosequencing-based bacterial pathogen identification in a pediatric hospital setting. *J. Clin. Microbiol.* 45 (9), 2985–2992.
- Luo, T., Jiang, L., et al., 2011. A multiplex real-time PCR melting curve assay to detect drug resistant mutations of *Mycobacterium tuberculosis*. *J. Clin. Microbiol.*
- Luong, M.L., Clancy, C.J., et al., 2011. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. *Clin. Infect. Dis.* 52 (10), 1218–1226.
- Mackay, I.M. (Ed.), 2007. *Real-Time PCR in Microbiology: From Diagnosis to Characterization*. Caister Academic Press, Norfolk, UK.
- Mackay, I.M., Jacob, K.C., et al., 2003. Molecular assays for detection of human metapneumovirus. *J. Clin. Microbiol.* 41 (1), 100–105.
- Maiden, M.C., Bygraves, J.A., et al., 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. *Proc. Natl. Acad. Sci. USA* 95 (6), 3140–3145.
- Marin, M., Munoz, P., et al., 2007. Molecular diagnosis of infective endocarditis by real-time broad-range polymerase chain reaction (PCR) and sequencing directly from heart valve tissue. *Medicine (Baltimore)* 86 (4), 195–202.
- Marlowe, L., Mistry, R.D., et al., 2010. Blood culture contamination rates after skin antiseptics with chlorhexidine gluconate versus povidone-iodine in a pediatric emergency department. *Infect. Control Hosp. Epidemiol.* 31 (2), 171–176.
- Marsh, T.L., Saxman, P., et al., 2000. Terminal restriction fragment length polymorphism analysis program, a web-based research tool for microbial community analysis. *Appl. Environ. Microbiol.* 66 (8), 3616–3620.
- Martinez, D.A., Nelson, M.A., 2010. The next generation becomes the now generation. *PLoS Genet.* 6 (4), e1000906.
- Massire, C., Ivy, C.A., et al., 2011. Simultaneous identification of mycobacterial isolates to the species level and determination of tuberculosis drug resistance by PCR followed by electrospray ionization mass spectrometry. *J. Clin. Microbiol.* 49 (3), 908–917.
- Matar, G.M., Swaminathan, B., et al., 1993. Polymerase chain reaction-based restriction fragment length polymorphism analysis of a fragment of the ribosomal operon from *Rochalimaea* species for subtyping. *J. Clin. Microbiol.* 31 (7), 1730–1734.
- Mayer, L.W., 1988. Use of plasmid profiles in epidemiologic surveillance of disease outbreaks and in tracing the transmission of antibiotic resistance. *Clin. Microbiol. Rev.* 1 (2), 228–243.
- Mazmanian, S.K., Liu, C.H., et al., 2005. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell* 122 (1), 107–118.
- Meijer, C.J.L.M., Berkhof, J., et al., 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. *Int. J. Cancer* 124, 516–520.
- Merante, F., Yaghoobian, S., et al., 2007. Principles of the xTAG respiratory viral panel assay (RVP Assay). *J. Clin. Virol.* 40 (Suppl 1), S31–35.

- Metzgar, D., Baynes, D., et al., 2010. Initial identification and characterization of an emerging zoonotic influenza virus prior to pandemic spread. *J. Clin. Microbiol.* 48 (11), 4228–4234.
- Metzgar, D., van Belkum, A., et al., 1998. Random amplification of polymorphic DNA and microsatellite genotyping of pre- and posttreatment isolates of *Candida* spp. from human immunodeficiency virus-infected patients on different fluconazole regimens. *J. Clin. Microbiol.* 36 (8), 2308–2313.
- Metzker, M.L., 2010. Sequencing technologies – the next generation. *Nat. Rev. Genet.* 11 (1), 31–46.
- Meudt, H.M., Clarke, A.C., 2007. Almost forgotten or latest practice? AFLP applications, analyses and advances. *Trends Plant Sci.* 12 (3), 106–117.
- Millar, B., Moore, J., et al., 2001. Molecular diagnosis of infective endocarditis—a new Duke's criterion. *Scand. J. Infect. Dis.* 33 (9), 673–680.
- Millar, B.C., Xu, J., et al., 2002. Risk assessment models and contamination management: implications for broad-range ribosomal DNA PCR as a diagnostic tool in medical bacteriology. *J. Clin. Microbiol.* 40 (5), 1575–1580.
- Millar, B.C., Xu, J., et al., 2007. Molecular diagnostics of medically important bacterial infections. *Curr. Issues Mol. Biol.* 9 (1), 21–39.
- Miller, M.B., Tang, Y.W., 2009. Basic concepts of microarrays and potential applications in clinical microbiology. *Clin. Microbiol. Rev.* 22 (4), 611–633.
- Mitchell, P.S., Germer, J.J., Yao, J.D.C., 2011. In: Persing, D.H., Tenover, F.C., Tang, Y.W., Nolte, F.S., Hayden, R.T., Van Belkum, A. (Eds.), *Laboratory Design and Operations. Molecular Microbiology: Diagnostic Principles and Practice*. American Society for Microbiology, Washington, D.C.
- Mohammadi, T., Reesink, H.W., et al., 2005. Removal of contaminating DNA from commercial nucleic acid extraction kit reagents. *J. Microbiol. Methods* 61 (2), 285–288.
- Monstein, H.J., Kihlstrom, E., et al., 1996. Detection and identification of bacteria using in-house broad range 16S rDNA PCR amplification and genus-specific DNA hybridization probes, located within variable regions of 16S rRNA genes. *APMIS* 104 (6), 451–458.
- Moore, J.E., Millar, B.C., et al., 2001. A rapid molecular assay for the detection of antibiotic resistance determinants in causal agents of infective endocarditis. *J. Appl. Microbiol.* 90 (5), 719–726.
- Morgan, J.L., Darling, A.E., et al., 2010. Metagenomic sequencing of an in vitro-simulated microbial community. *PLoS ONE* 5 (4), e10209.
- Mothershed, E.A., Whitney, A.M., 2006. Nucleic acid-based methods for the detection of bacterial pathogens: present and future considerations for the clinical laboratory. *Clin. Chim. Acta* 363 (1–2), 206–220.
- Mueller, N.J., Kaplan, V., et al., 1999. Diagnosis of *Cardiobacterium hominis* endocarditis by broad-range PCR from arterio-embolic tissue. *Infection* 27 (4–5), 278–279.
- Muhl, H., Kochem, A.J., et al., 2010. Activity and DNA contamination of commercial polymerase chain reaction reagents for the universal 16S rDNA real-time polymerase chain reaction detection of bacterial pathogens in blood. *Diagn. Microbiol. Infect. Dis.* 66 (1), 41–49.
- Mullis, K.B., Faloona, F.A., 1987. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. *Methods Enzymol.* 155, 335–350.
- Munoz, N., Bosch, F.X., et al., 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N. Engl. J. Med.* 348, 518–527.
- Munoz, P., Bouza, E., et al., 2008. Heart valves should not be routinely cultured. *J. Clin. Microbiol.* 46 (9), 2897–2901.
- Muyzer, G., de Waal, E.C., et al., 1993. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. *Appl. Environ. Microbiol.* 59 (3), 695–700.
- Nadkarni, M.A., Martin, F.E., et al., 2002. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. *Microbiology* 148 (Pt 1), 257–266.
- Nakamura, S., Yang, C.S., et al., 2009. Direct metagenomic detection of viral pathogens in nasal and fecal specimens using an unbiased high-throughput sequencing approach. *PLoS ONE* 4 (1), e4219.
- Nakauchi, M., Yasui, Y., et al., 2011. One-step real-time reverse transcription-PCR assays for detecting and subtyping pandemic influenza A/H1N1 2009, seasonal influenza A/H1N1, and seasonal influenza A/H3N2 viruses. *J. Virol. Methods* 171 (1), 156–162.
- Nicolle, L.E., Bialkowska-Hobrzanska, H., et al., 1992. Clonal diversity of methicillin-resistant *Staphylococcus aureus* in an acute-care institution. *Infect. Control Hosp. Epidemiol.* 13 (1), 33–37.
- Nikkari, S., Lopez, F.A., et al., 2002. Broad-range bacterial detection and the analysis of unexplained death and critical illness. *Emerg. Infect. Dis.* 8 (2), 188–194.
- Nocker, A., Camper, A.K., 2009. Novel approaches toward preferential detection of viable cells using nucleic acid amplification techniques. *FEMS Microbiol. Lett.* 291 (2), 137–142.
- Nolte, F.S., Marshall, D.J., et al., 2007. MultiCode-Plx system for multiplexed detection of seventeen respiratory viruses. *J. Clin. Microbiol.* 45 (9), 2779–2786.
- Notomi, T., Okayama, H., et al., 2000. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* 28 (12), E63.
- Oh, T., Kim, C., et al., 2004. Development and clinical evaluation of highly sensitive DNA microarray for detection and genotyping of human papillomaviruses. *J. Clin. Microbiol.* 42 (7), 3272–3280.
- Osborne, C.A., Rees, G.N., et al., 2006. New threshold and confidence estimates for terminal restriction fragment length polymorphism analysis of complex bacterial communities. *Appl. Environ. Microbiol.* 72 (2), 1270–1278.
- Ott, S.J., Musfeldt, M., et al., 2004. Quantification of intestinal bacterial populations by real-time PCR with a universal primer set and minor groove binder probes: a global approach to the enteric flora. *J. Clin. Microbiol.* 42 (6), 2566–2572.
- Overdevest, I.T., Williemsens, I., et al., 2011. Evaluation of the DiversiLab typing method in a multicenter study assessing horizontal spread of highly resistant gram-negative rods. *J. Clin. Microbiol.* 49 (10), 3551–3554.
- Pabbaraju, K., Tokaryk, K.L., et al., 2008. Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. *J. Clin. Microbiol.* 46 (9), 3056–3062.
- Palacios, G., Druce, J., et al., 2008. A new arenavirus in a cluster of fatal transplant-associated diseases. *N. Engl. J. Med.* 358 (10), 991–998.
- Pallen, M.J., Loman, N.J., et al., 2010. High-throughput sequencing and clinical microbiology: progress, opportunities and challenges. *Curr. Opin. Microbiol.* 13 (5), 625–631.
- Pareek, C.S., Smoczynski, R., et al., 2011. Sequencing technologies and genome sequencing. *J. Appl. Genet.*
- Patton, R.G., Schmitt, T., 2010. Innovation for reducing blood culture contamination: initial specimen diversion technique. *J. Clin. Microbiol.* 48 (12), 4501–4503.
- Peterson, J., Garges, S., et al., 2009. The NIH Human Microbiome Project. *Genome Res.* 19 (12), 2317–2323.
- Petrosino, J.F., Highlander, S., et al., 2009. Metagenomic pyrosequencing and microbial identification. *Clin. Chem.* 55 (5), 856–866.
- Petti, C.A., 2007. Detection and identification of microorganisms by gene amplification and sequencing. *Clin. Infect. Dis.* 44 (8), 1108–1114.
- Petti, C.A., Bosshard, P.P., Brandt, M.E., Clarridge III, J.E., Feldblyum, T.V., Foxall, P., Furtado, M.R., Pace, N., Procop, G., 2008a. Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing; Approved Guideline. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA (MM18-A).
- Petti, C.A., Hillyard, D., 2007. Value of RVP in clinical settings: older adults. *J. Clin. Virol.* 40 (Suppl 1), S53–54.
- Petti, C.A., Simmon, K.E., et al., 2008b. Culture-Negative intracerebral abscesses in children and adolescents from *Streptococcus anginosus* group infection: a case series. *Clin. Infect. Dis.* 46 (10), 1578–1580.
- Petti, C.A., Simmon, K.E., et al., 2008c. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. *J. Clin. Microbiol.* 46 (5), 1780–1784.
- Pitout, J.D., Campbell, L., et al., 2009. Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of *Escherichia coli* clone ST131 producing CTX-M. *J. Clin. Microbiol.* 47 (4), 1212–1215.
- Polley, S.D., Boadi, S., et al., 2011. Detection and species identification of microsporidial infections using SYBR Green real-time PCR. *J. Med. Microbiol.* 60 (Pt 4), 459–466.
- Pounder, J.L., Williams, S., et al., 2005. Repetitive-sequence-PCR-based DNA fingerprinting using the DiversiLab system for identification of commonly encountered dermatophytes. *J. Clin. Microbiol.* 43 (5), 2141–2147.
- Pounder, J.L., Hansen, D., et al., 2006. Identification of *Histoplasma capsulatum*, *Blastomyces dermatitidis*, and *Coccidioides* species by repetitive-sequence-based PCR. *J. Clin. Microbiol.* 44 (8), 2977–2982.
- Pounder, J.L., Simmon, K.E., et al., 2007. Discovering potential pathogens among fungi identified as nonsporulating molds. *J. Clin. Microbiol.* 45 (2), 568–571.
- Procop, G.W., 2007. Molecular diagnostics for the detection and characterization of microbial pathogens. *Clin. Infect. Dis.* 45 (Suppl 2), S99–S111.
- Pruesse, E., Quast, C., et al., 2007. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. *Nucleic Acids Res.* 35 (21), 7188–7196.
- Qin, J., Li, R., et al., 2010. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464 (7285), 59–65.
- Quince, C., Lanzen, A., et al., 2009. Accurate determination of microbial diversity from 454 pyrosequencing data. *Nat. Methods* 6 (9), 639–641.
- Raoult, D., Casalta, J.P., et al., 2005. Contribution of systematic serological testing in diagnosis of infective endocarditis. *J. Clin. Microbiol.* 43 (10), 5238–5242.
- Reeder, J., Knight, R., 2009. The 'rare biosphere': a reality check. *Nat. Methods* 6 (9), 636–637.
- Reier-Nilsen, T., Farstad, T., et al., 2009. Comparison of broad range 16S rDNA PCR and conventional blood culture for diagnosis of sepsis in the newborn: a case control study. *BMC Pediatr.* 9, 5.
- Relman, D.A., Falkow, S., 1992. Identification of uncultured microorganisms: expanding the spectrum of characterized microbial pathogens. *Infect. Agents Dis.* 1 (5), 245–253.
- Relman, D.A., Schmidt, T.M., et al., 1992. Identification of the uncultured bacillus of Whipple's disease. *N. Engl. J. Med.* 327 (5), 293–301.
- Renesto, P., Gautheret, D., et al., 2000. Determination of the rpoB gene sequences of *Bartonella henselae* and *Bartonella quintana* for phylogenetic analysis. *Res. Microbiol.* 151 (10), 831–836.
- Rice, P.A., Madico, G.E., 2005. Polymerase chain reaction to diagnose infective endocarditis: will it replace blood cultures? *Circulation* 111 (11), 1352–1354.
- Rodrigue, S., Malmstrom, R.R., et al., 2009. Whole genome amplification and de novo assembly of single bacterial cells. *PLoS ONE* 4 (9), e6864.
- Rogers, G.B., Bruce, K.D., 2010. Next-generation sequencing in the analysis of human microbiota: essential considerations for clinical application. *Mol. Diagn. Ther.* 14 (6), 343–350.
- Rogers, G.B., Hart, C.A., et al., 2003. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. *J. Clin. Microbiol.* 41 (8), 3548–3558.



- Rogers, G.B., Stressmann, F.A., et al., 2008. Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections. *Diagn. Microbiol. Infect. Dis.* 62 (2), 133–141.
- Rood, I.G., Koppelman, M.H., et al., 2008. Development of an internally controlled PCR assay for broad range detection of bacteria in platelet concentrates. *J. Microbiol. Methods* 75 (1), 64–69.
- Rosey, A.L., Abachin, E., et al., 2007. Development of a broad-range 16S rDNA real-time PCR for the diagnosis of septic arthritis in children. *J. Microbiol. Methods* 68 (1), 88–93.
- Rovero, C., Greub, G., et al., 2005. PCR detection of bacteria on cardiac valves of patients with treated bacterial endocarditis. *J. Clin. Microbiol.* 43 (1), 163–167.
- Saglani, S., Harris, K.A., et al., 2005. Empyema: the use of broad range 16S rDNA PCR for pathogen detection. *Arch. Dis. Child.* 90 (1), 70–73.
- Sait, L., Galic, M., et al., 2003. Secretory antibodies do not affect the composition of the bacterial microbiota in the terminal ileum of 10-week-old mice. *Appl. Environ. Microbiol.* 69 (4), 2100–2109.
- Saravolatz, L.D., Manzor, O., et al., 2003. Broad-range bacterial polymerase chain reaction for early detection of bacterial meningitis. *Clin. Infect. Dis.* 36 (1), 40–45.
- Savage, D.C., 1977. Microbial ecology of the gastrointestinal tract. *Annu. Rev. Microbiol.* 31, 107–133.
- Schabereiter-Gurtner, C., Nehr, M., et al., 2008. Evaluation of a protocol for molecular broad-range diagnosis of culture-negative bacterial infections in clinical routine diagnosis. *J. Appl. Microbiol.* 104 (4), 1228–1237.
- Schloss, P.D., Handelsman, J., 2006. Introducing SONS, a tool for operational taxonomic unit-based comparisons of microbial community memberships and structures. *Appl. Environ. Microbiol.* 72 (10), 6773–6779.
- Schopp, B., Holz, B., et al., 2010. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. *J. Med. Virol.* 82, 605–615.
- Schutte, U.M., Abdo, Z., et al., 2008. Advances in the use of terminal restriction fragment length polymorphism (T-RFLP) analysis of 16S rRNA genes to characterize microbial communities. *Appl. Microbiol. Biotechnol.* 80 (3), 365–380.
- Schuurman, T., de Boer, R.F., et al., 2004. Prospective study of use of PCR amplification and sequencing of 16S ribosomal DNA from cerebrospinal fluid for diagnosis of bacterial meningitis in a clinical setting. *J. Clin. Microbiol.* 42 (2), 734–740.
- Scott, L.J., Gunson, R.N., et al., 2010. A new multiplex real-time PCR test for HSV1/2 and syphilis: an evaluation of its impact in the laboratory and clinical setting. *Sex Transm. Infect.* 86 (7), 537–539.
- Shyu, C., Soule, T., et al., 2007. MiCA: a web-based tool for the analysis of microbial communities based on terminal-restriction fragment length polymorphisms of 16S and 18S rRNA genes. *Microb. Ecol.* 53 (4), 562–570.
- Sibley, C.D., Duan, K., et al., 2008a. Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. *PLoS Pathog.* 4 (10), e1000184.
- Sibley, C.D., Grinwis, M.E., et al., 2011. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. *PLoS One* 6 (7), e22702 (Epub 2011 Jul 28).
- Sibley, C.D., Parkins, M.D., et al., 2008b. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. *Proc. Natl. Acad. Sci. USA* 105 (39), 15070–15075.
- Simen, B.B., Simons, J.F., et al., 2009. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naïve patients significantly impact treatment outcomes. *J. Infect. Dis.* 199 (5), 693–701.
- Simmon, K.E., Croft, A.C., et al., 2006. Application of SmartGene IDNS software to partial 16S rRNA gene sequences for a diverse group of bacteria in a clinical laboratory. *J. Clin. Microbiol.* 44 (12), 4400–4406.
- Simmon, K.E., Hall, L., et al., 2008a. Phylogenetic analysis of viridans group streptococci causing endocarditis. *J. Clin. Microbiol.* 46 (9), 3087–3090.
- Simmon, K.E., Mirrett, S., et al., 2008b. Genotypic diversity of anaerobic isolates from bloodstream infections. *J. Clin. Microbiol.* 46 (5), 1596–1601.
- Smith, G.J., Vijaykrishna, D., et al., 2009. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. *Nature* 459 (7250), 1122–1125.
- Sontakke, S., Cadenas, M.B., et al., 2009. Use of broad range 16S rDNA PCR in clinical microbiology. *J. Microbiol. Methods* 76 (3), 217–225.
- Stephenson, M.F., Mfunu, L., et al., 2010. Molecular characterization of the polymicrobial flora in chronic rhinosinusitis. *J. Otolaryngol. Head Neck Surg.* 39 (2), 182–187.
- Tang, P., Chiu, C., 2010. Metagenomics for the discovery of novel human viruses. *Future Microbiol.* 5 (2), 177–189.
- Tang, Y.W., 2009. Duplex PCR assay simultaneously detecting and differentiating *Bartonella quintana*, *B. henselae*, and *Coxiella burnetii* in surgical heart valve specimens. *J. Clin. Microbiol.* 47 (8), 2647–2650.
- Tanner, M.A., Goebel, B.M., et al., 1998. Specific ribosomal DNA sequences from diverse environmental settings correlate with experimental contaminants. *Appl. Environ. Microbiol.* 64 (8), 3110–3113.
- Tenover, F.C., Gay, E.A., et al., 2009. Comparison of typing results obtained for methicillin-resistant *Staphylococcus aureus* isolates with the DiversiLab system and pulsed-field gel electrophoresis. *J. Clin. Microbiol.* 47 (8), 2452–2457.
- Tevfik Dorak, M. (Ed.), 2006. Real-time PCR. BIOS Advanced Methods. Taylor & Francis Group, New York, NY.
- Thomson-Carter, F.M., Carter, P.E., et al., 1989. Differentiation of staphylococcal species and strains by ribosomal RNA gene restriction patterns. *J. Gen. Microbiol.* 135 (7), 2093–2097.
- Thuny, F., Fournier, P.E., et al., 2010. Investigation of blood culture-negative early prosthetic valve endocarditis reveals high prevalence of fungi. *Heart* 96 (10), 743–747.
- Thurman, K.A., Warner, A.K., et al., 2011. Detection of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella* spp. in clinical specimens using a single-tube multiplex real-time PCR assay. *Diagn. Microbiol. Infect. Dis.* 70 (1), 1–9.
- Touinssi, M., Reynaud-Gaubert, M., et al., 2011. Parvovirus 4 in French in-patients: a study of hemodialysis and lung transplant cohorts. *J. Med. Virol.* 83 (4), 717–720.
- Towner, J.S., Sealy, T.K., et al., 2008. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. *PLoS Pathog.* 4 (11), e1000212.
- Tu, O., Knott, T., et al., 1998. The influence of fluorescent dye structure on the electrophoretic mobility of end-labeled DNA. *Nucleic Acids Res.* 26 (11), 2797–2802.
- Turnbaugh, P.J., Hamady, M., et al., 2009. A core gut microbiome in obese and lean twins. *Nature* 457 (7228), 480–484.
- Turnbaugh, P.J., Ley, R.E., et al., 2007. The human microbiome project. *Nature* 449 (7164), 804–810.
- van Belkum, A., Scherer, S., et al., 1998. Short-sequence DNA repeats in prokaryotic genomes. *Microbiol. Mol. Biol. Rev.* 62 (2), 275–293.
- van Belkum, A., Tassios, P.T., et al., 2007. Guidelines for the validation and application of typing methods for use in bacterial epidemiology. *Clin. Microbiol. Infect.* 13 (Suppl 3), 1–46.
- van Gent, M., Bart, M.J., et al., 2011. SNP-based typing: a useful tool to study *Bordetella pertussis* populations. *PLoS ONE* 6 (5), e20340.
- Vandecasteele, S.J., Frans, J., et al., 2002. Contamination management of broad-range ribosomal DNA PCR: where is the evidence? *J. Clin. Microbiol.* 40 (10), 3885 (author reply 3885–3886).
- Vernet, G., Saha, S., et al., 2011. Laboratory-based diagnosis of pneumococcal pneumonia: state of the art and unmet needs. *Clin. Microbiol. Infect.* 17 (Suppl 3), 1–13.
- Versalovic, J., 2009. Arrays and medical microbiology: e pluribus unum. *Arch. Pathol. Lab. Med.* 133 (4), 537–541.
- Voldstedlund, M., Norum Pedersen, L., et al., 2008. Broad-range PCR and sequencing in routine diagnosis of infective endocarditis. *APMIS* 116 (3), 190–198.
- Volokhov, D., Chizhikov, V., et al., 2003. Microarray-based identification of thermophilic *Campylobacter jejuni*, *C. coli*, *C. lari*, and *C. upsaliensis*. *J. Clin. Microbiol.* 41 (9), 4071–4080.
- Vos, P., Hogers, R., et al., 1995. AFLP: a new technique for DNA fingerprinting. *Nucleic Acids Res.* 23 (21), 4407–4414.
- Walker, G.T., Fraiser, M.S., et al., 1992a. Strand displacement amplification—an isothermal, in vitro DNA amplification technique. *Nucleic Acids Res.* 20 (7), 1691–1696.
- Walker, G.T., Little, M.C., et al., 1992b. Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system. *Proc. Natl. Acad. Sci. USA* 89 (1), 392–396.
- Walters, W.A., Caporaso, J.G., et al., 2011. PrimerProspector: de novo design and taxonomic analysis of barcoded polymerase chain reaction primers. *Bioinformatics* 27 (8), 1159–1161.
- Wang, C., Mitsuya, Y., et al., 2007a. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. *Genome Res.* 17 (8), 1195–1201.
- Wang, F., Massire, C., et al., 2011. Molecular characterization of drug-resistant *Mycobacterium tuberculosis* isolates circulating in China by multilocus PCR and electrospray ionization mass spectrometry. *J. Clin. Microbiol.* 49 (7), 2719–2721.
- Wang, Q., Garrity, G.M., et al., 2007b. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl. Environ. Microbiol.* 73 (16), 5261–5267.
- Welsh, J., McClelland, M., 1990. Fingerprinting genomes using PCR with arbitrary primers. *Nucleic Acids Res.* 18 (24), 7213–7218.
- Whitcombe, D., Brownie, J., et al., 1998. A homogeneous fluorescence assay for PCR amplicons: its application to real-time, single-tube genotyping. *Clin. Chem.* 44 (5), 918–923.
- White, T., Bruns, T., Lee, S., Taylor, J., 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: D.G., Innis, A., Sninsky, J.J., White, T.J. (Eds.), *PCR Protocols: A Guide to Methods and Applications*. Academic Press, San Diego, CA, pp. 315–322.
- Wilson, J.W., Limper, A.H., et al., 2011. Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity. *Diagn. Microbiol. Infect. Dis.* 69 (2), 145–152.
- Wilson, K.H., Blitchington, R.B., et al., 1990. Amplification of bacterial 16S ribosomal DNA with polymerase chain reaction. *J. Clin. Microbiol.* 28 (9), 1942–1946.
- Wise, M.G., Healy, M., et al., 2007. Species identification and strain differentiation of clinical *Candida* isolates using the DiversiLab system of automated repetitive sequence-based PCR. *J. Med. Microbiol.* 55 (Pt 6), 778–787.
- Wolcott, R.D., Cox, S.B., et al., 2010. Healing and healing rates of chronic wounds in the age of molecular pathogen diagnostics. *J. Wound Care* 19 (7), 272–278 (280–271).
- Wolcott, R.D., Gontcharova, V., et al., 2009a. Evaluation of the bacterial diversity among and within individual venous leg ulcers using bacterial tag-encoded FLX and titanium amplicon pyrosequencing and metagenomic approaches. *BMC Microbiol.* 9, 226.
- Wolcott, R.D., Gontcharova, V., et al., 2009b. Bacterial diversity in surgical site infections: not just aerobic cocci any more. *J. Wound Care* 18 (8), 317–323.

- Wolcott, R.D., Rhoads, D.D., et al., 2010. Chronic wounds and the medical biofilm paradigm. *J. Wound Care* 19 (2), 45–46 (48–50, 52–43).
- Wolfs, P.F., Bruggeman, C.A., et al., 2011. Replacing traditional diagnostics of fecal viral pathogens by a comprehensive panel of real-time PCRs. *J. Clin. Microbiol.* 49 (5), 1926–1931.
- Wolk, D.M., Blyn, L.B., et al., 2009. Pathogen profiling: rapid molecular characterization of *Staphylococcus aureus* by PCR/electrospray ionization-mass spectrometry and correlation with phenotype. *J. Clin. Microbiol.* 47 (10), 3129–3137.
- Woo, P.C., Lau, S.K., et al., 2008. Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories. *Clin. Microbiol. Infect.* 14 (10), 908–934.
- Woyke, T., Tighe, D., et al., 2010. One bacterial cell, one complete genome. *PLoS ONE* 5 (4), e10314.
- Wu, G.D., Lewis, J.D., et al., 2010. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. *BMC Microbiol.* 10, 206.
- Xu, J., Millar, B.C., et al., 2003. Employment of broad-range 16S rRNA PCR to detect aetiological agents of infection from clinical specimens in patients with acute meningitis—rapid separation of 16S rRNA PCR amplicons without the need for cloning. *J. Appl. Microbiol.* 94 (2), 197–206.
- Xu, Z.Q., Cheng, W.X., et al., 2011. Development of a real-time PCR assay for detecting and quantifying human bocavirus 2. *J. Clin. Microbiol.* 49 (4), 1537–1541.
- Yamamoto, T., Zhou, X., et al., 2009. Bacterial populations in the vaginas of healthy adolescent women. *J. Pediatr. Adolesc. Gynecol.* 22 (1), 11–18.
- Zhang, Y., Szustakowski, J., et al., 2009. Bioinformatics analysis of microarray data. *Methods Mol. Biol.* 573, 259–284.
- Zucol, F., Ammann, R.A., et al., 2006. Real-time quantitative broad-range PCR assay for detection of the 16S rRNA gene followed by sequencing for species identification. *J. Clin. Microbiol.* 44 (8), 2750–2759.

### Further reading

- Lander, E.S., Linton, L.M., et al., 2001. Initial sequencing and analysis of the human genome. *Nature* 409 (6822), 860–921.
- Simmon, K.E., Pounder, J.I., et al., 2007. Identification of an emerging pathogen, *Mycobacterium massiliense*, by rpoB sequencing of clinical isolates collected in the United States. *J. Clin. Microbiol.* 45 (6), 1978–1980.